FRAXE in the Newfoundland population by Dohey, Amanda
  
 
FRAXE IN THE NEWFOUNDLAND POPULATION 
 
by 
Amanda Dohey 
 
 
 
A thesis submitted to the School of Graduate Studies in  
partial fulfillment of the requirements for the degree of  
 
 
 
Master of Science in Medicine - Human Genetics 
Memorial University of Newfoundland 
 
 
 
May, 2018  
St. John’s, Newfoundland 
 
 
ii 
 
Abstract 
 
Children, especially boys, can present to their primary care physician, pediatrician, or 
genetics program with developmental delay and/or intellectual disability. FRAXE is a rare 
cause of intellectual disability caused by expansion and methylation of the CCG repeats in the 
5’ untranslated region of the FMR2 gene. Although the phenotype associated with FRAXE is 
not well defined, it has been reported to include: mild (IQ 50-69) to borderline (70-79) 
intellectual disability, learning problems, communication problems and overactivity with no 
consistent dysmorphology. 
 In the Canadian province of Newfoundland and Labrador, prior to initiation of the 
current study, two families segregating FMR2 expansions had been identified. The purpose of 
this study was to determine the prevalence of FRAXE among boys referred to the Provincial 
Medical Genetic Program for intellectual disability and/or developmental delay; to 
characterize FRAXE positive families; and to determine if there is a common ancestor 
connecting these families. This was accomplished by reviewing the charts of boys seen in the 
Provincial Medical Genetics Program from 1994 to 2004 that had unexplained developmental 
delay. This review resulted in the discovery of a FRAXE positive boy and his full mutation 
sister. During this time two additional FRAXE families were referred to the Provincial 
Medical Genetics Program. Using microsatellite markers three of the four FRAXE positive 
families were found to share a common haplotype of 1.8 Mb.  
The minimum prevalence rate in this male pediatric population was found to be 1 in 
7737 which is a six fold increase compared with the reported prevalence rate for FRAXE of 1 
in 50,000 or 1 in 23,423.  Our data supports routine testing of FMR2 expansions in boys with 
intellectual disability in the NL population.      
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Chapter 1 – Introduction 
 
1.1 Developmental Delay 
Developmental delay is defined as a significant lag in physical, cognitive, 
behavioural, emotional, and/or social development. The delay must be present in at least 
two of these areas and persistent. These conditions can be attributed to a multitude of 
diagnoses including intellectual disability (ID), cerebral palsy (CP), Down syndrome and 
autism spectrum disorder (ASD) while many others cannot be attributed to a specific 
diagnosis. The 2012 Canadian Survey on Disability reported that 0.6% of Canadian adults 
(aged 15 years and older) were identified as having a developmental disability
1
. The most 
prevalent underlying causes were autism spectrum disorder (ASD), cerebral palsy (CP), 
and Down syndrome.  
  
1.2 Intellectual Disability 
Intellectual disability (ID) is defined by the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-V) as deficits in intellectual functioning and adaptive 
functioning in the conceptual, social, and practical areas of living. Intellectual functioning 
is considered an individual’s ability to learn through both academics and experience. It 
captures reasoning, problem solving, abstract thinking and judgement. Adaptive 
functioning refers to deficits in activities of daily living, including but not limited to 
2 
 
 
communication, participation, independent living and social interaction at home, school, 
and work
2
. To be diagnosed with ID, the individual’s symptoms must date back to early 
development and not have occurred later in life due to an injury, which would be referred 
to as a neurocognitive disorder.  
The intelligence quotient (IQ) is a common tool used to measure intellectual 
function. ID is characterized by an IQ < 70 and levels of ID are referred to as mild (IQ = 
50-70), moderate (IQ = 35-50), severe (IQ = 20-35), profound (IQ ≤ 20) or unable to 
classify
3
. The most recent version of the DSM has removed the reference to IQ scores to 
indicate the level of ID severity and has proposed using the individual’s adaptive 
functioning level across all aspects of life
2
. However, many practicing clinicians still refer 
to IQ scores and they are commonly reported in the literature.  
ID is the most frequent reason for referral to pediatric genetic services
4
. ID can 
have a wide variety of causes including exposure of the fetus to toxins during 
development such as drugs and/or alcohol or maternal infection. Prematurity at birth or 
problems during the birthing process such as oxygen deprivation can also cause ID. 
Illness during development, injury to the brain and/or poor social conditions also can alter 
normal childhood development, particularly in terms of a child’s cognitive abilities. 
Genetic factors are thought to contribute to 25 to 50% of all cases of ID
5
. ID can be 
isolated or part of a broader syndrome. The worldwide prevalence of ID is estimated to be 
1%
4
. Approximately 75 to 90% of those with ID have mild ID.  
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1.2.1 Common forms of Intellectual Disability  
As described above there are several causes for ID but the most common include 
Fetal Alcohol Spectrum disorder (FASD), Down syndrome and Fragile X syndrome.  
 
1.2.1.1 Fetal Alcohol Spectrum Disorder  
FASD is the leading cause of preventable ID
6
. It is caused by the mothers’ 
consumption of alcohol during pregnancy. Health Canada estimates that more than 3,000 
babies a year are born in Canada with FASD
7
. The severity of the effects of alcohol 
consumption depends on numerous factors, including the amount of alcohol consumed, 
the duration and timing of the consumption. Features of FASD include a small head 
(microcephaly), facial dysmorphology, prenatally and/or postnatally restricted growth, 
learning disabilities, ID, hyperactivity, attention deficiencies, problems with hearing and 
vision, and a wide variety of congenital malformations including renal and cardiac. 
Dysmorphic facial features characteristic of FASD include short palpebral fissures with 
widely spaced eyes, a short nose and a bow-shaped mouth with thin upper lip. The facial 
abnormalities associated with FASD are due to the consumption of alcohol during critical 
periods of development for the fetus, therefore not all children with FASD will exhibit 
facial dysmorphology
8
.  
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1.2.1.2 Down Syndrome  
Down syndrome, also known as, Trisomy 21, is the most common form of ID 
worldwide and occurs in approximately 1 per 1,000 babies born each year in the United 
States
9
. A survey of Down syndrome rates in Canada between 2005 and 2013 reported 
that 1 in 750 live-born babies in Canada has Down syndrome
10
. Ninety-five percent of 
individuals with Down syndrome have an extra copy of chromosome 21. The remaining 
5% of cases are due to either a Robertsonian translocation, whereby a portion of 
chromosome 21 is translocated to another chromosome (usually chromosome 14 or 22), 
or mosaicism, whereby only a proportion of an individual’s cells have an additional 
chromosome present. Although Down syndrome is a genetic condition, it is rarely 
inherited. It is possible for an unaffected parent harbouring a balanced Robertsonian 
translocation to pass on this rearrangement to his or her offspring which can become 
unbalanced resulting in a loss or gain of genetic material
11
.  
Down syndrome has a distinct phenotype consisting of mild to moderate ID, 
characteristic facial features and often specific major congenital malformations, usually 
involving the heart and/or gastrointestinal tract. Specific facial features include up 
slanting palpebral fissures, epicanthic folds, flat nasal bridge and a protruding tongue. 
Other typical dysmorphia include single palmar creases, short curved fifth fingers, and a 
wide space between first and second toes. Additional phenotypic features include low 
muscle tone and short stature
9
.  
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1.2.1.3 Fragile X syndrome – Historical delineation 
Fragile X syndrome (FXS), was originally published as Martin-Bell syndrome. It 
has been referred to in the literature as fragile X mental retardation syndrome and as 
marker X syndrome. It was first described in 1943 by James Martin and Julia Bell
12
 and 
affected males were ascertained because of the presence of a cytogenetic fragile site on 
the X chromosome. This specific fragile site is referred to as folic acid type, rare, 
fra(X)(q27.3) A or FRAXA. In general, cytogenic fragile sites refer to chromosomal 
regions that are susceptible to breaks or gaps and were first identified in 1969 by Herbert 
Lubs. These fragile sites become apparent after exposing dividing white cells to certain 
culture conditions, such as a folate-deficient medium or by treating with chemical agents 
such as aphidicolin
13
. Over 100 different fragile sites have been identified and common 
fragile sites are considered to be present in all humans. Rare fragile sites occur in less 
than 5% of the population and have been associated with ID and also have implications in 
cancer genetics
14
. FXS was the first disease described to be associated with a specific 
fragile site. However, the FRAXA fragile site is not consistently expressed in all males 
with FXS. 
It is the second most common cause of ID, the most prevalent cause of ID in 
males and the most common cause of inherited ID
15
.  
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1.3 Genetics and Intellectual Disability  
As stated in section 1.2, 25 to 50% of ID cases are thought to be attributed to 
genetic factors
5
. Over 700 genes have been linked to X-linked, autosomal dominant and 
autosomal recessive forms of ID
4
.  
Briefly, inheritance is the process by which genetic information is passed on from 
a parent to his or her offspring. Mendelian inheritance is defined by two factors – the 
chromosome on which the mutated allele resides (autosome or sex chromosome) and 
whether the phenotype is dominant or recessive. Dominant diseases require only one 
mutated allele in order to cause disease whereas recessive conditions are expressed when 
both parents pass on the mutated allele to their offspring. Monogenic diseases are 
autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive or Y-
linked
12
. X-linked diseases carry important implications for males, who carry only a 
single X chromosome; X-linked recessive mutations are typically expressed in males, 
whereas females with one X-linked mutation are usually healthy carriers and do not 
express disease features. 
 
1.3.1 Syndromic vs non-syndromic X-linked Intellectual Disability  
Historically, the X chromosome was the main focus for studying ID due to the 
unbalanced sex ratio of ID incidence, with males being more commonly affected than 
females
16
. X-linked intellectual disability (XLID) accounts for 5 to 10% of male cases of 
ID
17
. At least 102 genes that have been linked to 160 different XLID diseases (Figure 
1.1). XLID can be further subdivided into syndromic (S-XLID) and non-syndromic ID 
7 
 
 
(NS-XLID). To be considered a syndromic form of ID, one or more clinical features must 
be present in addition to the ID, for example dysmorphic facial features and/or birth 
defects. ID is considered to be non-syndromic when ID is the sole clinical feature 
present
5
. The majority of the 102 XLID-associated genes identified reported in Lubs et al. 
(2012) are associated with S-XLID; however, overlap exists between mutations in these 
genes and S-XLID and NS-XLID forms of the disease Figure 1.1.A
17
. 
FXS, the most common cause of inherited ID, is the most widely recognized and 
common form of S-XLID
15
. It is caused by mutations in the Fragile X mental retardation 
1 (FMR1) gene, which maps to Xq27.3 and contains 17 exons spanning 38 kilobases (kb). 
Ninety-nine percent of individuals with FXS have a FMR1 loss-of-function mutation due 
to expansions of the polymorphic CGG repeat (> than 200 repeats) in the 5’ untranslated 
region (5’ UTR) of the gene15. This hypermethylation in the FMR1 promotor results in 
inhibition of the FMR1 transcript and subsequently complete loss of, or a significant 
reduction in the level of, the Fragile X mental retardation protein (FMRP). There are four 
classes of FMR1 repeats: normal (5 to 44 repeats), intermediate or grey zone (45 to 54 
repeats), premutation (55 to 200 repeats) or full mutation (>200 repeats). Clinical 
manifestations associated with each repeat size in discussed in detail below (section 
1.3.2). 
Prevalence rates of Fragile X full mutations have been reported as 1 in 7000 or 1 
in 5000 to 7000 males depending on the source
15,18
. Prevalence rates of full mutations in 
females have been reported as 1 in 11,000 or 1 in 4000 to 6000 females
15,18
.
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Figure 1.1 – A. Genes with identified mutations that cause S-XLID. B. Genes with identified mutations that cause NS-
XLID. The genes listed on the right of the figure are associated with both S-XLID and NS-XLID. Reprinted with permission 
from Fragile X and X-Linked Intellectual disability: Four Decades of Discovery Lubs, Stevenson, Schwartz (2012)
17
.
A B 
9 
 
 
Approximately two thirds of XLID cases are thought to be non-syndromic
3
. 
Thirty-nine genes identified to be associated with NS-XLID are shown in Figure 1.1B
17
. 
The genes listed on the right of the figure are associated with both S-XLID and NS-
XLID.  
Unlike FXS, which is the most common form of syndromic ID, Fragile X E 
mental retardation (FRAXE), is a rare and non-syndromic form of ID. FRAXE is caused 
by triplet repeat expansions in the 5’ UTR region of the Fragile X mental retardation 2 
(FMR2) gene, which is approximately 600 kb downstream of the FMR1 gene, and maps 
to Xq28. It is composed of 21 coding exons with several possibilities of alternative 
splicing for exons 2, 3, 5, 7 and 21
19
. The gene encodes a protein that localizes in neurons 
in the neocortex, Purkinje cells of the cerebellum and granule cell layer of the 
hippocampus
20
. It is highly expressed in the placenta and the adult and fetal brain
21
. 
As in FXS, FRAXE has a folate-sensitive fragile site, folic acid type, rare 
fra(X)(q28) E (FRAXE); however, the FRAXA and FRAXE fragile sites are 
undistinguishable from each other using cytogenetic methodology
22
. Both fragile sites, 
FRAXA and FRAXE, are not consistently expressed in all males with full FMR1 and 
FMR2 expansions.  
FRAXE was first described in 1992 by Sutherland and Baker and initially was not 
considered to be associated with a disease phenotype. The identification of the FMR2 
gene in 1996 allowed for the link between FRAXE and ID to be recognized
23-25
. Since 
that time a total of 40 probands have been reported in the literature. Section 1.3.8 
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provides a complete an in-depth review of the literature with an emphasis on the 
phenotype of FRAXE positive cases.  
Insight from the Fmr2 knock-out (KO) mouse model indicates that Fmr2 is 
expressed in several tissues besides the brain including bone, cartilage, hair follicles, 
lung, tongue, tendons, salivary glands and major blood vessels
26
. As well, Fmr2 knock 
out mice were found to have impaired learning and memory. FMR2 is part of a family of 
genes which also includes AFF1/AF4, AFF3/LAF4 and AFF4/AF5q31
27
. Redundancy 
within this family of genes may explain the fact that many males with FMR2 full 
mutations have a mild to borderline phenotype
28
. 
As with FXS, FRAXE has four classes of FMR2 repeats: normal (6 to 30 repeats), 
premutation (61 to 200 repeats) and full mutations (>200 repeats). There is some debate 
as to what is considered an intermediate allele, with some papers suggesting 31 to 60 
repeats
29,30
 and others 41 to 60 repeats
31,32
.  
In 1996, Brown estimated the prevalence rate of FRAXE to be rare at 1 in 50,000 
males
33
. This rate was based on prevalence of FXS in the population and an expected 
ratio of FRAXE to FRAXA at approximately 4%. In 2000, Youings calculated an updated 
prevalence of 1 in 23,423 based on their five-year study in combination with a large 
sample set from another study, Crawford et al.
34
.  
Due to the differences in frequency between FRAXA and FRAXE in the 
population it is not surprising that the amount of clinical testing for FRAXE is much 
lower than for FRAXA. Just two years after FMR2 was identified as the gene involved in 
FRAXE Brown made a strong case against routine FRAXE screening, stating that all 
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individuals thus far who had a FRAXE positive result had a positive Xq27 fragile site test 
but were negative for an FMR1 expansion
33
. Therefore, FRAXE testing should be offered 
only when a fragile site was identified and FMR1 was negative. Knight and colleagues 
(1996) felt that FRAXE was a relatively rare, but significant, cause of ID in the 
population and screening should be offered where appropriate.  
 
1.3.2 Clinical Manifestations 
 
1.3.2.1 Fragile X syndrome – Syndromic X-linked Intellectual Disability  
Males with a FMR1 full expansion, accompanied by aberrant methylation, 
typically have moderate ID. Following puberty, full expansion males often have a 
characteristic appearance. Distinct features include: a long narrow face with prominent 
forehead (macrocephaly), a prominent chin, a high arched palate, large, protruding ears 
and large testes (macroorchidism) after puberty
35
. A recent review of the literature by 
Ciaccio et al. (2017) demonstrated that full mutation males have a multi-system condition 
which includes musculoskeletal, cardiovascular, central nervous system, neuropsychiatric 
and eye features. Over 74% of full mutation males had electroencephalogram (EEG) 
anomalies, 50% had joint hypermobility, and 50% had pectus excavatum. Psychomotor 
delay and ID was seen in all patients. Ninety percent of individuals had aggressive 
behaviours, 74 to 84% had attention problems, 50 to 66% were hyperactive and 58 to 
86% had anxiety disorder. ASD was noted in 30 to 50% of cases and 30% had sleep 
problems
15
. Approximately 30% of young children with FXS do not have obvious 
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dysmorphic features, however, delayed developmental milestones in young children, 
particularly in regard to psychomotor ability and speech are often apparent
15,35
.  
Females heterozygous for a full FMR1 expansion may have the physical and 
behavioural features seen in full expansion males but at a lower frequency and with 
milder involvement than males
35
. Full expansion females have a 30% chance of having 
normal intelligence and a 25% chance of having ID (IQ <70)
15
.  
 
1.3.1.2 FRAXE – Non-syndromic X-linked Intellectual Disability 
FRAXE is a rare cause of ID caused by expansion and methylation of the CCG 
repeats in the 5’ UTR of the FMR2 gene. Although the phenotype associated with 
FRAXE is not well defined, it has been reported to include: mild (IQ 50 to 69) to 
borderline (70 to 79) ID, learning problems, communication problems, and overactivity, 
with no consistent dysmorphology
36
. There have been very few reported females affected 
by FRAXE due to fully methylated expansions. 
 
1.3.3 FMR1-related Disorders 
A FMR1 repeat size between 55 and 200 is considered a premutation and presents 
itself as a very different disease than FXS. FMR1 premutations have been associated with 
fragile X-associated tremor/ataxia syndrome (FXTAS) in males and to a lesser extent in 
females. Females may also exhibit premature ovarian failure (POF). In the normal 
population 1 in 850 males and 1 in 300 females carry a FMR1 premutation
18
.  
13 
 
 
1.3.3.1 Fragile X-associated tremor ataxia syndrome (FXTAS) 
FXTAS is a neurodegenerative disorder characterized by intension tremor, 
cerebellar ataxia, progressive neurodegeneration, parkinsonism and cognitive decline
37
. 
Individuals harbouring a premutation allele (55 to 200 repeats) of the FMR1 gene have an 
increased risk of developing FXTAS later in life. Age is a significant risk factor for 
FXTAS development in males; approximately one third of male premutation carriers 
older than 50 are affected by FXTAS, and over 50% of affected by age 70 to 90 years of 
age. In comparison, FXTAS was detected in only 16.5% of female premutation carriers
38
.  
FXTAS has major and minor diagnostic criteria with both neuroradiologic and 
clinical signs. A definite diagnosis of FXTAS requires the presence of a premutation in 
the FMR1 gene, as well as, white matter lesions in the middle cerebellar peduncles and/or 
brain stem on magnetic resonance imaging (MRI) (two major neuroradiologic signs), in 
addition to either intention tremor or gait ataxia (two major clinical signs). Individuals 
can also be given a probable diagnosis of FXTAS, which requires one major 
neuroradiologic sign and one minor clinical sign or two major clinical signs. A possible 
FXTAS diagnosis includes one minor neuroradiologic sign and one major clinical sign. 
Minor neuroradiologic signs include white matter lesions in the cerebral white matter on 
MRI and moderate to generalized atrophy. Clinical minor signs include parkinsonism, 
moderate to severe working memory deficits and executive cognitive function deficits
35
.  
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1.5.3.2 Primary Ovarian Failure (POF) 
Primary ovarian failure (POF), also known as, primary ovarian insufficiency 
(POI) is defined as the cessation of menses for 6 months before the age of 40 associated 
with follicle-stimulating hormone (FSH) levels observed in the menopausal range
39
. POF 
incidence is estimated at 1 in 1000 women under the age of 30, 1 in 250 women around 
35 years old, and 1 in 100 women at 40 years of age. Overall, the prevalence of POF in 
the general population is approximately 1 to 2%
40
. A number of genes have been 
associated with POF including FMR1 and FMR2; the transforming growth factor beta 
family members bone morphogenetic protein 15 (BMP15) and inhibin alpha (INHA); the 
gonadotropin receptors for luteinizing hormone (LHR), and FSH (FSHR); transcription 
factors such as forkhead box L2 (FOXL2) and forkhead box O3 (FOXO3); the nuclear 
hormone receptors estrogen receptor alpha (ESR1) and beta (ESR2) and the orphan 
splicing factor 1 (SF1); and aromatose, or cytochrome P450 family 19 subfamily member 
1 (CYP19A1)
41
.  
The prevalence of FMR1 premutation females in the normal population is 
approximately 1 in 300
18
 with the estimate of POF in FMR1 premutation carriers ranging 
from 12.9% to 21%
42,43
. Women with FMR1 full mutations do not exhibit POF. Exactly 
how the presence of FMR1 premutations, but not full mutations, leads to ovarian 
dysfunction is unknown; however, the FMRP protein is highly expressed in the germ cells 
of the fetal ovary
44,45
. One theory is that elevated levels of FMR1 may lead to increased 
oocyte development, resulting in an overall decrease in the number of oocytes. Another 
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theory is that the mRNA produced by the premutation alleles may have a toxic effect, 
leading to elevated levels of follicular atresia
41
.  
In a study on 507 women, FMR1 repeat size was compared with ovarian 
dysfunction
42
. The authors found the highest prevalence of POF in women with 80 to 99 
repeats, which they termed a medium size premutation. Individuals with higher 
premutation sizes (>100) and lower premutation sizes (59 to 79), exhibited significantly 
lower rates of POF, 12.5% and 5.9% respectively, in comparison to individuals with 80 to 
99 repeats (18.6%)
42
. Furthermore, they found that carrying an intermediate or low 
premutation contributed to reducing the age of menopause onset. In addition, younger 
premutation women were similar to non-carriers with respect to FSH levels, suggesting 
that significant fertility problems may not be an issue for these women before the age of 
30.  
 
Table 1.1 – Summary of FMR1 repeat size and associated disease phenotype in 
males and females 
 
FMR1 Repeat Size 
Associated Phenotype 
Male 
Associated Phenotype 
Female 
Normal (5 to 44) Normal Normal 
Intermediate (45 to 54) Normal Normal 
Premutation (55 to 200) 
At risk of developing 
FXTAS 
At risk of developing 
POF 
At risk of developing 
FXTAS 
Full mutation (>200) 
FXS                        
(100% with ID) 
~ 25% with ID               
~ 30% with normal 
intellect 
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1.3.4 FMR2 related associations  
Unlike FMR1, no known diseases have been associated with premutations in 
FMR2. However, several research groups have investigated the effect of the four FMR2 
repeat allele classes on phenotype manifestations.  
 
1.3.4.1 Intermediate Alleles and Learning Disabilities 
Murray et al. (1998) tested 992 boys with learning disabilities and compared them 
to controls which were derived from the non-transmitting X chromosome of the mothers. 
The authors found a significant excess of FMR2 intermediate alleles in the test population 
(p=0.036) suggesting a link between intermediate alleles and learning disabilities
39
. 
In 1999, Crawford and colleagues assessed the frequency of FMR2 intermediate 
and premutations alleles in a large cohort of children between the ages of 7 and 10 
(n=2,652) who attended special-education needs (SEN) classes in public school. The 
control group was the non-transmitting X allele from the mother. They found no excess of 
intermediate or premutation alleles in the SEN population and no significant difference 
between the cases and the controls
46
.  
Finally, in a screening of 276 boys aged 2 to 18 years with mental impairment or 
learning disabilities, three intermediate alleles (31 to 60 repeat sizes) were identified in 
the at-risk group compared with none in 207 controls; however, this difference did not 
reach statistical significance
31
.  
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With conflicting evidence, it is difficult to determine if intermediate alleles in 
FMR2 play a role in learning disabilities. In order to confirm or dispute the findings from 
Murray additional studies are needed in individuals with learning disabilities.  
 
1.3.4.2 Intermediate Alleles and Parkinson’s disease  
A study by Annesi et al. (2004) examined 203 males with idiopathic Parkinson’s 
disease (PD) and compared FMR2 allele size with a healthy male cohort of 370 
individuals. The authors did not identify any premutations or full mutations in either 
population, but did observe an excess of intermediate alleles (31 to 60 repeats) in the PD 
cohort which was statistically significant. In the Parkinson’s cohort, thirteen intermediate 
alleles (6.4% [13/203]) were observed compared with only one in the controls (0.3% 
[1/370]). The authors also investigated the test population in terms of clinical phenotype 
including cognitive performances, but did not find a difference between those who had an 
intermediate allele and those with an allele in the normal range
29
.  
A follow up study in 2011 did not support the previous study’s findings. Costa 
and colleagues (2011) tested 206 PD patients and 227 controls and compared allele sizes 
across both groups, defining intermediate alleles as being in the size range of 31 to 61 
repeats. Although they found twice as many intermediate alleles in the test group (2.9% 
[6/206]) as to the control group (1.3% [3/227]), these frequencies did not reach statistical 
significance
32
.  
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Overall the information available for FMR2 intermediate alleles is limited and 
what is available is conflicting. More information is needed to determine if FMR2 
intermediate alleles have any phenotypic effect on an individual.  
 
1.3.4.3 Microdeletions and Primary Ovarian Failure 
It has been suggested that the FMR2 gene may play a role in POF, particularly 
with respect to microdeletions involving the gene. In 1998, Murray’s research group 
published their work on 147 women with POF, of whom 17% had familial POF, 
investigating the role of the FMR1 and FMR2 genes. They found 2% of chromosomes in 
the POF group carried FMR1 premutations (p = 4.3x10
-3
); 8% of chromosomes harboured 
FMR1 premutations if the data was restricted to only include individuals with familial 
POF (p = 0.0086). No FMR2 premutations or full mutations were identified in this cohort. 
They also noted that the POF group contained a significant excess of minimal alleles (<11 
repeats) in FMR2 in comparison to the controls (p = 0.046)
39
. As one woman showed a 
smaller FMR2 amplicon than what would be expected from an allele with no CCG 
repeats, the authors speculated she must have carried a small deletion. A follow up 
investigation specifically interrogating FMR2 microdeletions in a POF population 
identified six (2.8%) women with minimal FMR2 alleles (allele size of ≤11); of these six, 
three had deletions within the gene
47
. In comparison, of 2,434 women in the control 
group, 41 had minimal alleles yet only one had an FMR2 microdeletion. In the study 
group, two out of three deletions were near or included the FMR2 transcription start site.  
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There have been no additional findings in the literature to support the theory that 
microdeletions or premutations in the FMR2 gene cause POF. In two recent published 
review articles exploring the causes of POF, FMR2 was listed as an associated gene
41,48
. 
However, both reviews only reference the original work by Murray
39
. 
Similar to the work published on intermediate alleles in individuals with learning 
disabilities and Parkinson’s disease, more research is needed to determine if 
microdeletions in FMR2 play a significant role in women with POF. For women who 
have POF, FMR2 testing may be warranted, especially in there is a family history of ID or 
developmental delay.   
 
1.3.5 Mechanism of Disease 
Although FXS is classified as a syndromic form of ID and FRAXE as a non-
syndromic form of ID, mutations in the FMR1 and FMR2 genes are similar in their 
mechanism of action - both are triplet repeat disorders with expansions of the 
polymorphic nucleotide repeat leading to gene silencing. 
 
1.3.5.1 Triplet Repeat Disorders 
A new class of genetic disease, termed triplet repeat disorders, was recognized in 
the 1990s
49,50
. These disorders are characterized by an expansion within the affected gene 
of a segment of DNA that contains a repeat of three nucleotides. In the general 
population, the repeat range in the associated gene are polymorphic however, lower 
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repeat numbers are typically observed. As the gene is passed from one generation to the 
next, the number of repeats is unstable (dynamic mutation), and can increase during 
replication leading to an alteration of gene expression and function
11
. These triplet repeat 
disorders can vary in the nucleotides associated with the repeat (e.g. CCG, CGG, AAG), 
the location of the repeat with respect to the gene (exon, intron, 5’ UTR, 3’ UTR), the 
mechanism of disease (gain-of-function, loss-of-function) and the inheritance pattern 
(autosomal dominant, autosomal recessive, X-linked). Trinucleotide repeat expansions 
account for 16 neurological disorders ranging from ID syndromes to neurodegenerative 
disease
51
.  
In terms of FXS, this is a loss-of-function triplet repeat disorder caused by 
expansions of the polymorphic CGG repeat in the 5’ UTR of FMR1 with an X-linked 
inheritance pattern. FRAXE is also a loss-of-function mutation with an X-linked 
inheritance pattern, however, it is caused by expansions of CCG repeats in the 5’ UTR of 
the FMR2 gene. For both diseases, an expansion of repeats greater than 200 triggers 
methylation of the CpG islands in the gene’s promotor. This hypermethylation causes the 
chromatin to condense preventing the binding of specific transcription factors and 
therefore silencing the gene
52
. It is the silencing of the gene and therefore loss of or 
reduction of the protein that causes the phenotype associated with FXS or FRAXE 
depending on the gene involved. 
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1.3.5.2 Deletions 
Less than 1% of individuals with FXS have a partial or full deletion of FMR1
35
. 
Deletions in FMR1 were first reported in 1992 through the identification of individuals 
with a Fragile X phenotype, but normal FMR1 CGG repeat size
53,54
. Since that time, only 
a handful of additional cases have been observed with deletions involving FMR1 ranging 
from 355 base pairs (bp) to 13 megabases (Mb)
52
.  
Like FMR1, there have been rare cases of mutations in the FMR2 gene not 
associated with methylation/silencing of the gene. In 2007, Honda et al., reported two 
patients with chromosomal abnormalities involving the FMR2 gene. The first patient, a 3 
year old girl with mild ID, had a de novo balanced translocation, 46,XX,t(X;15) 
(q28;p11.2) resulting in a disruption between exon 3 and 4 of FMR2, with the intact X 
chromosome being predominantly inactive. This young girl had delayed development, 
was nonverbal and had febrile convulsions. The second child, a 23-month-old boy, had a 
deletion starting between exons 9 and 10 of FMR2 and up to and including five other 
genes, one of which was iduronate 2-sulfatase (IDS), a gene known to be responsible for 
the lysosomal storage disease, Hunter syndrome. He presented as a floppy infant with 
coarse facial features, unusually enlarged tongue, low muscle tone and abdominal 
swelling. Although it was difficult to distinguish which features were associated with the 
FMR2 deletion compared to the IDS deletion, there were several features that were 
present in this boy that have not been associated with Hunter syndrome, such as muscular 
hypotonia, hypothyroidism and gastroesophageal reflux
55
.  
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A deletion resulting in the complete loss of exon 3 in FMR2 was identified in two 
brothers with mild ID
56
. Both children had developmental delay in the areas of motor and 
language by their second year. Autistic features including impaired social interaction and 
communication as well as hand flapping, restricted interests and repetitive behaviours 
were noted. In both brothers, a 121 to 145 kilobase (kb) deletion in the FMR2 gene was 
identified by array comparative genomic hybridization (CGH) platform (Agilent 244K). 
Their younger brother was unaffected by developmental delay, but did have mild 
attention deficit and hyperactivity disorder (ADHD), and he did not harbour the deletion. 
The mother was a carrier for the deletion and was considered unaffected. A maternal aunt 
and uncle, who both had mild ID, were also screened for the deletion using Multiplex 
Ligation-dependent Probe Amplification (MLPA); only the uncle was found to harbour 
the same deletion as the brothers. The maternal aunt’s phenotype which was described as 
mild ID, was considered significantly different than the brothers and she had no 
behaviour abnormalities. The phenotype of the deletion-positive uncle was considered 
very similar to the brothers and he also exhibited autistic behaviours.   
In another study, two unrelated males with microdeletions in the FMR2 gene were 
identified using whole genome oligonucleotide array
57
. One patient had a loss of 
approximately 240 kb within exons 2 to 4 of FMR2. He presented at age 21.5 months 
with microcephaly. The parents reported that some early milestones were delayed, 
particularly speech. At 35 months, he was examined by a geneticist and had some 
dysmorphic features, including mild flattening of the occiput, prominent nasal tip, and 
bilateral fifth finger clinodactyly. The second patient had a 499.3 kb deletion that 
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included exons 1 and 2 of FMR2, along with an additional 343 kb segment upstream of 
FMR2. This patient also had a heterozygous 358 kb duplication of the 1q21.1 region. He 
was referred at 3 years 7 months of age with global developmental delay and behavioural 
problems and was not dysmorphic. He had substantial deficits in areas of social 
interaction, expressive and receptive language, and fine motor skills. He was withdrawn, 
unresponsive to affection, adverse to new situations and exhibited hand flapping. He had 
a positive family history for developmental delay, as his two older brothers had speech 
and language delays; they were unavailable for testing
57
.  
Several cases of deletions that involve both the FMR1 and FMR2 genes have been 
identified
58-62
; however, the phenotype associated with these deletions was attributed by 
the authors as being mainly due to the deletion of FMR1. Then in 2007, a female patient 
was reported who had ID and a large deletion which included FMR1, FMR2 and IDS
63
. 
Because there was sufficient iduronate 2-sulfatase (IDS) enzyme in her blood, the authors 
concluded that her phenotype was due to the deletion of FMR1 and FMR2.  
Recently, a male and his mother have been reported with a deletion that included 
FMR1, FMR2, and SLITRK2 (the SLIT and NTRK-like family member 2). This deletion 
was located within a paracentric inversion
64
. This male was described as not having the 
typical fragile X facial dysmorphology.  
In summary, when a deletion spans multiple genes, it is difficult to determine 
which genes contributed to which phenotypic features of the patient in question, 
especially when such events are rarely seen. Overall, deletions are an uncommon cause of 
FXS and FRAXE, but an important consideration when a patient presents with 
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unexplained ID and phenotypic features of these diseases. As microarray analysis 
becomes a more routine diagnostic test, more deletions may be identified. Moreover, 
whole genome sequencing (WGS) can more precisely define the breakpoints of deletions 
than microarrays and can identify structural rearrangement of the genome that are missed 
by other technologies. Hence over the next few years, there may be more reported cases 
that involve deletions and other structural variants (e.g. inversions) that involve FMR1 
and FMR2.  
 
1.3.5.3 Point Mutations 
Point mutations account for less than 1% of reported FXS cases
35
. The first report 
of an FMR1 point mutation associated with disease was in 1993 in a large Dutch family 
affected with X-linked liver glycogenosis
65
. One individual within this family presented 
with a large forehead, asymmetric long face, large ears, thick lips and macroorchidism 
without the presence of a fragile site, expansion of the FMR1 gene or hypermethylation. 
Sequencing of FMR1 identified a point mutation, c.1100T>A, resulting in a missense 
mutation (p.Ile376Asn). This was determined to be a de novo mutation as it was not 
present in the parents or any of the neurotypical siblings
65
. No functional work was 
presented in the paper to support this genotype-phenotype relationship.  
  More recently, a point mutation in FMR1 (c.797G>A; p.Gly266Glu) was 
identified in a 16 year old male with FXS
66
. The characteristic Fragile X dysmorphic 
features were noted in conjunction with disruptive outbursts, ADHD and ASD. 
Algorithms predicted this highly conserved amino acid change as damaging. Functional 
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analysis using an Fmr1 KO mouse model, western blotting, and co-immunoprecipitation 
showed the mutated protein could not perform normal key functions including mRNA 
binding and polyribosome association, suggesting that the variant was responsible for the 
phenotype of this patient
66
. 
In 2014, Handt et al. published a cohort of 508 males who met the criteria of 
Fragile X-like phenotype, including ID/developmental delay, and who were negative for 
FMR1 and FMR2 full mutations. These males were tested for point mutations in FMR1 
using high resolution melting analysis, and only two missense variants were identified in 
three clinically affected males. The first boy, who had psychomotor delay, language 
impairment and attention issues as well as above average height (98
th
 centile) carried a 
c.1444G>A (p.Gly482Ser) variant. The other two unrelated boys carried a c.1601G>A 
(p.Arg534His) variant; their phenotype was similar with respect to developmental delay 
and learning difficulties. One of these two boys also exhibited low attention span and 
behavioural outbursts and was macrocephalic with height and weight close to the 97
th
 
percentile
67
. The authors described all three boys as having a FXS like phenotype. The 
relevance of these variants requires further functional work to determine potential 
pathogenicity.  
Overall, FMR1 point mutations appear to be rare leading to less than 1% of the 
FXS observed in the population. However, testing for point mutations may be warranted 
for males presenting with a phenotype consistent with FXS who have an FMR1 repeat 
size that is within the normal range. 
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There have been no reported cases of point mutations causing disease in FMR2. 
The literature on FXS is vast in comparison with FRAXE publication, and given the rarity 
of FMR1 point mutations, it is possible that FMR2 point mutations do contribute to the 
FRAXE phenotype but have not been reported in the literature.  
 
1.3.6 Genetic Phenomenon Associated with Fragile X 
 
1.3.6.1 X-inactivation 
The mode of inheritance also contributes to the complicated etiology of FXS and 
FRAXE. X-linked diseases are caused by mutations in genes that are found on the X 
chromosome. A karyotypically normal female carries two X chromosomes. In order to 
compensate for gene dosage, one of the two X chromosomes is inactivated early in 
embryonic development, through a methylation process called X-inactivation. Under 
normal circumstances, the selection of which X is inactivated is random. The inactivated 
X chromosome can be observed cytologically as a heterochromatin mass called the Barr 
body.  
If a female carries a mutation on one of her two X chromosomes and random X-
inactivation occurs, one expects to see the normal allele expressed in approximately 50% 
of her cells and the mutant allele expressed in the other 50%. This is known as random X-
inactivation. This explains why the majority of females who carry a mutation in an X-
linked gene are “healthy carriers”. Females who are carriers of an X-linked mutation 
occasionally have disease manifestations, and the commonest mechanism through which 
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this occurs is skewed X-inactivation. In this scenario, the X chromosome with the normal 
allele is silenced in more than 50% of the cells. X-inactivation studies are typically 
performed on lymphocytes, and females with manifestations of X-linked disorders 
typically have a ratio of at least 90% to 10%
12
.  
As illustrated in Table 1.1 25% of females with FMR1 full expansions have ID, 
indicating that most females with full expansions do not have FXS. The associated 
phenotype, or lack thereof, in females is believed to be strongly connected to their X-
inactivation pattern
15
. In a recent case report, two daughters affected with FXS were 
found to carry a full FMR1 expansion with random X inactivation
68
. Their mother, who 
also carried a full expansion but who was phenotypically normal, had a non-random X 
inactivation pattern with the normal allele being predominantly active.  
There have been very few reports of females with full expansions of FMR2 who 
are affected with FRAXE. In one French family with seven individuals segregating full 
expansions, one female was identified to be severely affected
69
. This child had idiopathic 
West syndrome (infantile spasm syndrome), speech delay and mild to moderate ID (IQ 50 
to 60). She carried an expansion of 800 repeats, and had 22 to 28% cytogenetic fragile 
site expression. In comparison, her mother did not have ID or psychological problems yet 
had a FMR2 expansion of 750 repeats, with 12-15% fragile site expression. In contrast, in 
another study of two large families with FRAXE, four phenotypically normal females 
were identified who carried full FMR2 expansions that were fully methylated
70
. 
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1.3.6.2 Anticipation 
Anticipation, the phenomenon whereby the symptoms of a disease appear earlier 
or in a more severe form from one generation to the next generation, is another common 
feature of triplet repeat disorders. The size of the repeat is often an indicator of the 
severity of the disease, and in some cases, is also associated with its instability. In 
general, premutations are often not large enough to cause disease, but are large enough 
that they may become unstable when passed from one generation to the next
12
. The sex of 
the transmitting parent often also plays a role in the stability or more importantly, the 
instability of a premutation.  
In FXS, full expansions are only transmitted to offspring maternally, either by 
transmission of a full mutation allele or through expansion of a premutation allele
18
. 
Males with a premutation only transmit a premutation allele to their daughters. As males 
with FXS are severely affected, there is little data on male transmission of full expansions 
to their offspring; however, in a small study of four males with full expansions, only 
premutations were observed in their sperm
71
. 
 
1.3.6.3 Mosaicism 
Another feature associated with X-inactivation which can be observed in these 
diseases is mosaicism, in which two or more populations of cells with different genotypes 
exist within one individual. Mosaicism has been noted in males who have two or more 
different cell populations for either FMR1 CGG or FMR2 CCG repeats. Males who are 
size mosaics can have both a full mutation and premutation size repeat detected in blood. 
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Males who are methylation mosaics have also been reported. These individuals carry full 
mutations in both a methylated and unmethylated state
72
. Mosaicism for full mutations 
and premutations has been reported to occur in 12 to 41% of males with FXS
72,73
. This 
information is not available for FMR2.  
 
1.3.7 Testing for FMR1 and FMR 2 Mutations  
Historically, Fragile X positive patients were identified by the presence of a 
fragile site on Xq27.3 following exposure of cultured cells to a folate deficient medium. 
At that time, the FMR2 gene had not been identified, its association with disease was not 
known, and it was not possible to distinguish between the FMR1 and FMR2 fragile sites 
using cytogenetic means. With the identification of the FMR1 gene in 1991
74-77
, came a 
new approach for testing for FXS – Southern blots.  
Southern blotting is a technique for detecting specific DNA sequences by 
transferring restriction enzyme treated DNA fragments that have been separated by gel 
electrophoresis onto a filter membrane. This is then hybridized with a radioactive labelled 
probe such as StB12.3 or Ox1.9
12
. First described by Rousseau et al. (1991), double 
digestion by restriction enzymes such as EcoRI (non-methylation sensitive) and EagI 
(methylation sensitive) allows for the identification of a FMR1 and FMR2 expansion, as 
well as, associated methylation status. All wild type males have an EcoRI-EagI fragment 
of 2.8 kb, whereas all wild type females have two fragments – the 2.8 kb fragment and an 
inactive 5.2 kb fragment. EagI is inhibited by DNA methylation, and therefore, a full 
mutation male sample treated with EagI will not be digested by EagI and will be greater 
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than 5.2 kb in size
78
. Although Southern blotting has good sensitivity for detecting 
expansions, it does not give a precise repeat size. Southern blotting is also a labour 
intensive and expensive methodology with a long turnaround time that uses radioactivity, 
requires a large amount of DNA, and is technically difficult.  
For these reasons, polymerase chain reaction (PCR) has been the test of choice for 
FXS and FRAXE for a number of years. PCR can detect allele sizes within the normal, 
intermediate, and small premutation range, therefore eliminating the need for Southern 
blotting for a large number of FMR1 and FMR2 negative patients. Larger premutations 
and full mutations cannot be detected by PCR as they fail to amplify; therefore, any male 
sample that does not produce an amplicon, or female samples who appear homozygous in 
the normal range, must undergo further investigation using Southern blotting. 
Recently, several companies have produced kits that allow for the amplification of 
the CG-rich repeat sequences. The most widely used is Amplidex
TM
, produced by 
Asuragen, which can accurately detect full mutations up to 1,300 CGG repeats
22
 
(Asuragen, Austin, TX USA). This assay was approved for clinical use in Canada in 2013 
and is currently used in many of the clinical laboratories across the country. Although 
Amplidex
TM
 detects repeats in the full mutation range, it can only accurately size repeats 
in the premutation range (<200 repeats) and cannot detect methylation status, therefore, 
Southern blot is still a necessary step to determine methylation status. The Amplidex
TM 
kit is only used for interrogating the FMR1 gene and the company does not produce a 
similar kit for FMR2.  
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Another technique, Methylation-specific Multiplex Ligation Dependent Probe 
Amplification (MS-MLPA) can be used to investigate the methylation status of the CpG 
islands in the 5’ UTR of the FMR1 and FMR2 genes (MRC-Holland, Amsterdam, 
Netherlands). The MS-MLPA ME029 kit can only detect methylation of the FMR1 and 
FMR2 gene in males and cannot indicate repeat size. The kit also tests for deletions or 
duplications for some of the exons of FMR1 and FMR2.  
As technology advances, new methodologies for investigating the FMR1 and 
FMR2 genes will emerge. For now, standard protocol for most laboratories is PCR, 
followed by Southern blot, if warranted.   
 
1.3.8 FRAXE – An Elusive Phenotype  
 
1.3.8.1 FRAXE Studies in the Literature  
36 studies screening various cohorts for FMR2 expansions have been published. 
The at-risk populations screened have included children (male and female) with ID and/or 
academic difficulty and individuals with ASD, obsessive compulsive disorder (OCD), 
Parkinson’s disease (PD), and premature ovarian failure (POF) (Appendix L -
Supplementary Table S.1). Individuals with FMR2 full mutations were identified in 
eight of these 36 studies, specifically in seven ID cohorts and one OCD cohort with a 
frequency of 0.027% to 3.85%. A summary of the positive FRAXE findings are shown 
below.  
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Table 1.2 – Summary of the FRAXE male positive cases identified in FMR2 studies 
in the literature 
 
FRAXE Screening Studies 
Ref 
# of 
Individuals 
N
o
rm
a
l 
In
te
rm
ed
ia
te
 
P
re
m
u
ta
ti
o
n
 
M
u
ta
ti
o
n
 Cohort 
Criteria 
Origin 
79 
911 
908 
  
1
+ 
(+3) 
Negative for 
FMR1 
expansions 
United 
Kingdom M 
903 
F 
8 
80 
105 
   
1 ID patients 
Northeast 
Italy (sex N/A) 
81 
180 
179 
  
1 
ID (unknown 
etiology) 
Italy 
(sex N/A) 
82 
222 
  
0 1 
4-20 yrs in SNS 
for ID 
Spanish M 
182 
F   
40 
83 
232 
   
1 ID patients Italian 
(sex N/A) 
34 
3738 
3687 41 2 1 
boys 5-18 yrs 
in SNS 
England 
All Male 
84 
114 
   
1 
9-16 yrs in SNS 
with mild-mod 
ID 
Croatia 
M 
73 
F   
41 
85 
26 
25 
  
1 
males & 
females with 
OCD 
Utah, US M 
15 
F   
11 
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M = males; F = females; N/A = unavailable; SNS = special needs school; yrs = years; 
OCD = obsessive compulsive disorder. When available, the number of individuals tested 
is broken down in male and female. 
+
 Reference 79: Two related females were found to 
harbour an FMR2 expansion; only one positive FMR2 expansion was identified in the 
screened cohort, however, the article reports on three additional FRAXE positive cases; 
Most authors used the term MR (mental retardation) when the paper was published and, 
as this is no longer acceptable terminology, MR has been changed in the above table to 
ID.  
 
1.3.8.2 FMR2 Positive Cases 
Since the FMR2 gene was identified in 1992
86
, 40 probands have been reported in 
the literature (Table 1.3)
34,69,70,79-85,87-98
. A total of 80 full FMR2 expansion males and 71 
full FMR2 expansion females have been identified in these 40 families. 
 
Table 1.3 – Summary of FRAXE positive male probands in the literature and full 
expansion alleles identified in their family members 
 
Ref # of 
Probands 
(male) 
Type of 
Report: Family 
or Case Study 
# of Full 
Expansion
Male 
Relatives 
# of Full 
Expansion 
Female 
Relatives 
87 
2 Family 1 4 6 
Family 2 2 0 
88 1 Family 9 7 
89 
2 Family 1 2 9 
Family 2 4 7 
   90 + 
4 Family 1 2 1 
Family 2 4 2 
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Ref # of 
Probands 
(male) 
Type of 
Report: Family 
or Case Study 
# of Full 
Expansion
Male 
Relatives 
# of Full 
Expansion 
Female 
Relatives 
Family 3 1 2 
Family 4 1 2 
91 
4 Family A 1 2 
Family B 2 0 
Family C 5 1 
Family D 1 3 
   92 + 
3 Family 1 2 5 
Family 2 4 5 
Family 3 2 5 
79 4 Case 4 N/A 
   80 ^ 1 Case 1 N/A 
   81 ^ 1 Case 2 0 
93 
3 Family A 3 1 
Family B 1 1 
Family C 2 1 
82 1 Case 1 N/A 
70 
2 Family 1 3 4 
Family 2 1 1 
94 
2 Case 1 1 * 
Case 1 N/A 
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Ref # of 
Probands 
(male) 
Type of 
Report: Family 
or Case Study 
# of Full 
Expansion
Male 
Relatives 
# of Full 
Expansion 
Female 
Relatives 
83 1 Family 2 2 
95 1 Case 1 N/A 
34 1 Case 1 N/A 
96 2 Case 2 0 
84 1 Case 1 N/A 
97 1 Family 1 1 
69 1 Family 3 3 
85 1 Family 2 0 
98 1 Case 1 N/A 
Total 40  80 71 
 
+
 Reference 
90
 - Family 5 and 6 not listed here; description available in reference 
92
 (equivalent to 
Family 1 and 2). ^ These articles are from the same research group and it was not possible to 
determine if they referred to the same or different probands. * Not part of a family but a separate 
case (female) with a FMR2 expansion. N/A = not available or not applicable.  
 
 
Each article was reviewed and all information regarding the phenotype for each 
positive FRAXE male was recorded in a spreadsheet. Two articles provided no 
phenotypic information about the proband
34,80
. A condensed version of this chart is shown 
below (Table 1.4). Information was recorded based only on the description given by the 
author.  
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A blank field indicates that this information was missing from the description 
provided in the paper. If an individual was recorded as having no dysmorphic features 
this is indicated as ‘no’ under the dysmorphic heading; if there was no information 
regarding this feature, that field is blank. If the author described clinical features of the 
individual, but considered the person to be non-dysmorphic, this is also indicated. The 
presence of dysmorphism was commented on in 26 cases and 20/26 (77.9%) were 
considered to be nondysmorphic. A more detailed description of the dysmorphic features 
is summarized in Table 1.5. 
Although IQ and ID can be overlapping terms and IQ values can be used to 
determine ID, to avoid confusion they are recorded separately. In some articles, mild ID 
may have been reported, however, formal testing may not have occurred. The ID category 
is not inferred from the IQ testing value but instead refers to the authors’ specific 
comments on the individual’s level of ID. For most of the literature the term used was not 
ID but mental retardation (MR). As MR is no longer considered socially acceptable and 
has recently been replaced by the term ID, ID is indicated in the summary table below 
instead. In many instances, the authors referred to the disability as mild or severe MR.  
IQ scores were reported in 28 cases with a range of 45-128 and mean of 69. The 
presence or absence of ID was recorded in 41 cases: 2/41 (4.9%) had borderline ID, 12/41 
(29.3%) had mild ID, 5/41 (12.2%) had moderate ID and 5/41 (12.2%) had severe ID. 
Moderate to severe ID was recorded for one case (1/41 [2.4%]), and four cases (4/41 
[9.8%]) were just reported as having ID but the level of ID was not defined. Normal 
intelligence was recorded in 11/41 (26.8%) cases. One case (1/41 [2.4%]) was recorded as 
37 
 
 
having variable ID, but details were not specified. Combining all instances of ID, from 
borderline to severe, 73% of the cases (30/41) had some level of ID.  
The learning category indicates whether the affected individual was reported as 
having any difficulties in school. The abnormalities ranged from mild learning 
difficulties, such as alternative curriculum pathways for specific subjects, to attending a 
special school for individuals with ID. The presence or absence of learning problems was 
commented on for 29 of the cases, of which 27/29 (93.1%) reported there was some 
degree of academic difficulty. Of the 27 individuals reported to have learning problems, 
ten attended a special school (37%) for children with learning problems and/or ID.  
The language and speech category includes any problems related to 
communication such as delayed speech, stutter, repetitive speech and echolalia. If the 
individual just had delayed speech, that later resolved with age or therapy, this is 
indicated in the table as “delayed speech”. Language and/or speech abnormalities were 
recorded in 33/78 (42.3%) of the cases. In two cases, the language issue was delayed 
speech that resolved as the child got older. 
Fifteen individuals (15/78 [19.2%] had features of ADD or ADHD – three 
individuals were recorded as overactive, ten cases had attention problems and two males 
were recorded to have both overactivity and attention difficulties.  
Behavioural problems were noted in 17 cases and a description of the behavioural 
issue was noted in the comment section, if available.  
Although only two cases were reported as having a formal diagnosis of ASD, 
several authors reported autistic features in their cases. Combining the cases described as 
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having socialization deficits, hand mannerisms and/or echolalia with the cases described 
as having autistic features or ASD, fifteen individuals had features commonly associated 
with ASD. The role of FXS in ASD is well documented and may be an important point to 
consider for FRAXE as well
99
. 
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Table 1.4 – Condensed phenotype review of all FMR2 full mutation males in the literature 
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Table legend. 
++
 Could not be evaluated; Y = Yes; N = no; Nor = normal; Bord = borderline; SS = special school; Var = variable testing result seen; Mod = 
moderate; Sev = severe; Del = delayed; P = proband; Rel = relative; GU = great uncle; GF = grandfather; BR = brother; Nep = nephew; F=family; C= 
case; FM = full methylated; PM = partial methylation; Mos = mosaic; OCD = obsessive compulsive disorder; EEG = electroencephalogram. Note: a blank 
field indicates that this information was missing from the description provided in the publication. 
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Of the 80 full expansion males reported in the literature, the presence or absence 
of dysmorphic features was commented on for 39 males (48.9%) from 40 families. 
Authors included an overall statement about dysmorphology in 15 cases, six of whom 
were classified as dysmorphic (including one mildly dysmorphic). The published 
descriptions were reviewed by a geneticist (BF). Based on the presence of multiple minor 
physical abnormalities described in the manuscript, the geneticist classified certain 
additional individuals as dysmorphic, which is indicated in the table below as 
“dysmorphic based on the reported features”. This resulted in an additional 11 cases being 
classified as dysmorphic. Therefore, the total number of males that were dysmorphic were 
17/39 (43.6%). Of the seventeen cases that were dysmorphic, 9/17 (52.9%) had at least 
two dysmorphic features that are common features of FXS (macrocephaly/tall broad 
forehead, large ears, long facies). The description of the dysmorphic features reported by 
the authors for the full expansions males is given below (Table 1.5). 
 
 
 
 
Table 1.5 – Dysmorphic features observed in 39 FRAXE full expansion males from 
80 full expansion males reported in the literature 
Ref 
Individual ID 
from 
publication 
Dysmorphology 
Dysmorphic 
(as per the 
authors) ^ 
Dysmorphic 
Based on 
Reported 
Features 
At least 
two 
FXS 
features 
87 
 
 
Fam1 IV-8 
Proband 
 narrow and high arched 
palate 
No   
Fam1 III-8  
(uncle)  broad forehead 
   
Fam2 III-1 
Proband 
 high, broad forehead 
 epicanthic folds 
No   
88 
II-5 
Proband 
 macrocephaly 
 long narrow face 
 Yes Yes 
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Ref 
Individual ID 
from 
publication 
Dysmorphology 
Dysmorphic 
(as per the 
authors) ^ 
Dysmorphic 
Based on 
Reported 
Features 
At least 
two 
FXS 
features 
 
 
 
 
 
 
 
 midfacial hypoplasia 
 high arched palate 
II-4 
(twin brother) 
 macrocephaly 
 long narrow face 
 Yes Yes 
II-8 
(cousin) 
 macrocephaly 
 midfacial hypoplasia 
   
II-10 
(cousin) 
 macrocephaly 
 midfacial hypoplasia 
   
II-19 
(cousin) 
 macrocephaly 
 long narrow face 
 midfacial hypoplasia 
 high arched palate 
 long neck 
 Yes Yes 
III-1 
(nephew) 
 macrocephaly 
 long narrow face 
 midfacial hypoplasia 
 high arched palate 
 long, narrow ears 
 prominent jaw 
 long neck 
 Yes Yes 
III-3 
(nephew) 
 macrocephaly 
 long narrow face 
 midfacial hypoplasia 
 high arched palate 
 large ears 
 long neck 
 height (>3rd centile) 
 weight (>3rd centile) 
 Yes Yes 
III-18 
(cousin’s son) 
 long narrow face 
 midfacial hypoplasia 
 high arched palate 
 long neck 
 Yes No 
89 
Fam1 ID8 
Proband  encephalopathy 
No   
90 
 
 
Fam1 I-1  
(grandfather) 
 macrocephaly 
 narrow lower face 
 prominent eyebrows 
 large ears 
 Dupuytryn contracture 
 Yes Yes 
Fam1 III-2  
(grandson)  high arched palate 
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Ref 
Individual ID 
from 
publication 
Dysmorphology 
Dysmorphic 
(as per the 
authors) ^ 
Dysmorphic 
Based on 
Reported 
Features 
At least 
two 
FXS 
features 
Fam3 II.1 
Proband 
 macrocephaly 
 hypotelorism 
 epicanthic folds 
 small ears 
 prominent upper incisor 
 high arched palate 
 nipples were low placed 
 small hands/feet 
 Yes No 
91 
  
FamA II-3 
Proband  cleft lip/palate 
 No No 
FamD II-6 
Proband 
 hypertelorism 
 broad nasal bridge 
 anteverted nares 
 protruding tongue 
Yes Yes No 
92 
  
  
Fam2 III-1 
Proband 
 brachycephaly with 
normal head 
circumference 
 broad midface 
 narrow sloping forehead 
 prominent eyebrows 
 mild telecanthus 
 high arched palate 
 clinodactyly 
 narrow chest with pectus 
deformity (excavatum of 
lower sternum and 
carinatum of upper 
sternum) 
 blepharophimosis 
 broad nose and nares 
 wide nasal septum 
 mild kyphoscoliosis  
Yes Yes No 
Fam2 III-4  
(Brother) 
 brachycephaly 
 narrow sloping forehead 
 prominent eyebrows 
 broad neck 
 telecanthus, left  
 epicanthic fold 
 slight micrognathia 
 broad nose and nasal 
bridge with anteverted 
nostrils 
 Yes No 
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Ref 
Individual ID 
from 
publication 
Dysmorphology 
Dysmorphic 
(as per the 
authors) ^ 
Dysmorphic 
Based on 
Reported 
Features 
At least 
two 
FXS 
features 
 wide nasal septum 
 pectus deformity 
(excavatum of lower 
sternum and carinatum of 
upper sternum) 
 mild kyphoscoliosis 
Fam3 II-3 
Proband 
 microcephaly 
 brachycephaly 
 long narrow face 
 narrow forehead 
 flattened occiput 
 testis abnormal (vl l-
50ml, r-35 ml) 
 high arched palate 
 pectus excavatum 
 carinatus 
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Proband 
 microcephaly 
 stellate irides 
 thick lips and long upper 
lip 
 misplaced teeth 
 height (< 3rd centile)  
 weight (< 3rd centile) 
 hoarse voice 
 Yes 
(Mild) 
Yes No 
Proband 
 clinodactyly 
 café-au-lait 
No   
Proband  2 white patches in hair No   
Proband 
 height (>97th centile) 
 macrocephaly 
   
81 Proband 
 midface hypoplasia 
 hypotelorism 
 epicanthic folds 
 micrognathia 
 abnormal dental 
morphology 
 clinodactyly 
   
93 
 
FamC III-1 
(Brother of 
Proband) 
 small, simple pinnae  
 failure to thrive 
No   
FamC III-2          No   
82 Proband 
 Marfan like 
 long narrow face 
Yes Yes No 
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Ref 
Individual ID 
from 
publication 
Dysmorphology 
Dysmorphic 
(as per the 
authors) ^ 
Dysmorphic 
Based on 
Reported 
Features 
At least 
two 
FXS 
features 
 high arched palate 
 low posterior hairline 
 thoracic scolosis 
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Fam1 III-7 
Proband 
 midfacial hypoplasia 
 blepharophimosis 
   
Fam1 III-9  
(cousin)  midfacial hypoplasia 
   
Fam1 III-3  
(cousin) 
 long narrow face 
 midfacial hypoplasia 
 long nose 
   
Fam2 II-1 
Proband 
 macrocephaly 
 long face 
 midfacial hypoplasia 
 blepharmophimosi 
 Yes Yes 
83 
 
Proband 
 long face with high 
forehead  
 prominent jaw 
 mild hypertelorism 
 strabismus 
 low set ears 
 hypoplastic alae nasi 
 prominent lower lip 
 high arch palate 
 crowded teeth 
 narrow sloping shoulders 
 longer slender 
hands/fingers 
Yes Yes Yes 
Twin Brother   No   
96 Proband  cleft palate    
84 
 Proband 
 prominent high forehead 
 large prominent ears 
 Yes Yes 
69 
  
  
II-7 
Proband 
 hypertelorism 
 unfolded left ear 
Yes Yes No 
III-2 
(cousin’s son) 
 flat feet 
 length asymmetry of 
limbs 
No   
II-6 
(Brother)  cleft lip 
   
^ Comment from author if the individual was dysmorphic or not. Blank cell = no 
comment from authors. 
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1.8.2.3 Repeat range in the Published Data  
A review of the literature revealed the most common FMR2 allele size was 15 
with a mode range of 13 to 20 repeats depending on the population examined
29,30,46,89,100-
110
. 
 
Table 1.6 – Repeat range of the FMR2 allele observed in the literature 
Reference Population Repeat Range Mode 
89 At risk 6 25 15 
109 
At risk 7 35 16 
Control 10 23 13 
100 At risk 3 35 15 
111 At risk 7 25 16 
30 
At risk 8 87 15 
Control 8 41 15 
102 At risk 5 38 15 
101 
At risk 4 39 16 
Control 12 34 16 
103 At risk N/A N/A 16-18 
104 At risk N/A N/A 16 
110 At risk 1 43 16 
46 At risk 7 54 17.59 
105 Control 5 44 15 
106 At risk 8 48 20 
107 At risk 3 27 15 
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Reference Population Repeat Range Mode 
Control 8 27 15 
108 Control N/A N/A 15 
29 
 
At risk 5 54 14 
Control 11 37 14 
 
 
1.4 Study Rationale and Objectives  
In the Canadian province of Newfoundland and Labrador (NL), prior to initiation 
of the current study, two families segregating FMR2 expansions had been identified. This 
was unexpected due to the province’s relatively small population of 519,720112 and the 
reported rarity of FRAXE. We hypothesized this may be due to NL’s unique genetic 
architecture. The province is composed of a collection of genetic isolates. Its first 
colonies were established in the 17
th
 century from approximately 20,000 individuals from 
two main immigrant populations, Roman Catholics from the south of Ireland and 
Protestants from the south-west of England
113
. These settlers came to the island because 
of its rich fishing grounds and established coastal homes. Until relatively recently, travel 
between these communities was difficult and occurred mostly by sea. In addition, to 
geographical isolation and little emigration, religious segregation also occurred as 
individuals tended to marry into the same denomination. This, combined with large 
family sizes, makes NL an ideal place to study genetic disease.  
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Genetic isolates like NL often have a unique distribution of genetic disorders, 
reflecting those that were present in the population’s founders. Certain diseases may be 
over represented compared with more heterogeneous populations, while others may not 
be present at all. NL has the highest Canadian rate of colorectal cancer
114
 and the highest 
incidence of type 1 diabetes mellitus
115
. Founder effects have been identified for certain 
monogenic diseases including familial adenomatous polyposis coli syndrome (FAP)
116
, 
Lynch syndrome
117
, arrhythmogenic right ventricular cardiomyopathy/dysplasia type V 
(ARVD5)
118
 and hereditary diffuse gastric cancer syndrome
119
.  
On the other hand, FXS due to expansions in the X-linked FMR1 gene, which is 
the most common cause of inherited ID in most populations
4
, is virtually absent in NL: 
only one NL family with an FMR1 expansion has been identified through Eastern 
Health’s Province Medical Genetics Program (PMGP).  
 
 
1.7.1 Purpose and Objectives 
Building on a strong foundation of solving genetic disease, which is in partly due 
to the unique genetic isolates and large family size, the health care structure here is ideal. 
The PMGP is a centralized clinical service for investigating genetic disorders for the 
entire province. This, coupled with the local expertise in developmental delay and ID, as 
well as, the resource of the Newfoundland Genealogy Database, offers a unique 
opportunity to study FRAXE in the population. The proportion of identified FMR2 to 
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FMR1 mutations in NL was unusual and made it plausible that this population is enriched 
for FMR2 mutations.  
The purpose of this study was to determine the prevalence of FRAXE among boys 
referred to the PMGP for ID and/or developmental delay. Specifically, the objectives of 
this research were: 
1) To determine the prevalence of FMR2 mutations in FMR1-negative 
individuals through a comprehensive chart review; and 
2) To characterize FMR2 positive families and determine if there is a common 
ancestor connecting these families. 
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Chapter 2 – Methods 
 
 The purpose of this research project was to explore FRAXE in the Newfoundland 
and Labrador (NL) population. The recruitment phase of this study involved three 
different cohorts: 1) two known FRAXE NL families; 2) boys referred to the Provincial 
Medical Genetics Program (PMGP) with developmental delay of unknown etiology and 
negative FMR1 testing (referred to as the retrospective cohort); and 3) children with mild 
intellectual disability (ID) seen in the Child Development Clinic at the Janeway 
Children’s Health and Rehabilitation Center, St. John’s, who typically would not be 
referred for assessment by a clinical geneticist (referred to as the Janeway cohort).  
 FMR2 allele size was compared between the retrospective test population and 
controls, as well, the NL population was compared to the reported allele size in the 
literature. A review of the clinical phenotypes of the previously reported males with 
FRAXE was compiled.  
 Recruited participants were tested for FMR2 allele size through PCR and 
expansions were confirmed using an outside research facility. As NL has a unique genetic 
structure it was postulated the FRAXE families may share a common ancestor. To 
determine if this was the case, families were analyzed using the Newfoundland 
Genealogy Database. Haplotype analysis was performed on these families to determine if 
they shared a common haplotype region. A description of how this was accomplished is 
detailed below. Memorial University’s Health Research Ethics Board (HREB) approved 
this project [05.175]. 
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2.1 Participant Recruitment 
 
2.1.1 Known FRAXE Families 
At the time of this study, there were two unrelated, geographically separate NL 
families known to the PMGP. Both families were contacted by a genetic counsellor at the 
PMGP and asked if they would be interested in speaking to someone about a new 
research project investigating FRAXE.  
 
2.1.2 Retrospective Cohort 
2.1.2.1 Chart Review and Recruitment 
The SHIRE database from the PMGP was used to identify all individuals who 
were referred to genetic services from 1994 to 2004 for unexplained developmental delay. 
The charts were reviewed and participants were recruited using the following inclusion 
criteria: male; referred to genetics with development delay; received FMR1 testing and 
remained without a specific genetic diagnosis and was between the ages of 2 and 19 years 
at the time of testing. A parent was contacted and given a brief introduction to the study. 
Parents were informed that their participation was completely voluntary and if they 
agreed to participate, they could withdraw at any time (Appendix A). If the parent 
agreed, the family’s address was confirmed and 2 copies of the consent and a stamped 
return envelope were mailed.  
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In an Access database the following was recorded: child’s name, MCP (medical 
care plan), date of birth and DNA number; parents’ names and address; date of phone 
call, along with some details regarding the contents of the call; and date on which the 
consent form was mailed. The child was then given a study number and the chart was 
pulled for follow-up.  
A follow-up call was made two weeks later to confirm that the consent was 
received and to provide the parent with an opportunity to ask questions. Parents were 
asked to provide consent for their child. If the child was 12 years or older and could 
comprehend the details of the study, then he was included in the consent process 
(Appendix B). If the parent agreed to participate and the consent was not received within 
one month from the follow-up call, an additional call was made to remind the parent that 
testing for their child would not proceed until the signed consent was received. If after 
two months the consent had not been received and the parent had expressed interest in 
participating, a reminder letter along with an additional copy of the consent was sent 
(Appendix C). The reminder letter also indicated that if the consent was not received by 
the date specified, we would assume that the family was not interested in participating 
and no further attempts to contact them would be made.  
 
2.1.2.2 Chart Extraction 
All signed consents were placed in a locked filing cabinet. Once the consent was 
received, a chart extraction was completed (Appendix D). The chart extraction form 
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included sections for dysmorphology findings, growth parameters (height, weight and 
head circumference) and the results of biochemical, metabolic, molecular, cytogenetic, 
radiology and any other relevant testing. Also recorded was the date of first visit to 
genetics, reason for referral, referring physician, and positive family history of 
developmental delay, intellectual disability (ID) and/or learning problems. 
 
2.1.2.3 Sample Acquisition  
An aliquot of the DNA was requested from the Laboratory Medicine DNA Bank. 
For some of the participants there was no DNA remaining. In these cases, the parent was 
contacted and informed there was not a sample available for FMR2 testing. The parent 
was given the opportunity to withdraw from the study or to have the child provide a new 
blood sample. If the parent agreed to have the child’s blood drawn, a blood requisition 
form was mailed out to take to the family’s nearest blood collection service. An 
additional DNA consent form was sent to the parent to indicate options for the child’s 
sample once the study was complete (Appendix E). A letter to the parent accompanied 
the consent form to ensure parents understood the implications of storing their child’s 
DNA. (Appendix F). The letter indicated that if no response was received from the parent 
selecting an option for the child’s DNA once the study was completed, then the sample 
would be destroyed. Contact was made with the appropriate laboratory to arrange 
shipment of the blood once the sample was taken. DNA was then extracted according to 
the procedure detailed in section 2.2.1.  
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2.1.3 Janeway Cohort 
 
2.1.3.1 Janeway Recruitment 
The third phase of this study was to recruit participants through the Child 
Development Clinic at the Janeway Children’s Health and Rehabilitation Center, the local 
children’s hospital for the province. A brief presentation was given to introduce the child 
developmental pediatricians to the FRAXE study. The discussion focused on the purpose 
of the study, the inclusion criterion, what to do if a child met the inclusion criteria and 
how to track this information. Five child developmental pediatricians agreed to aid in the 
recruitment of this study.  
 
2.1.3.2 Tracking Form and Inclusion Criteria 
Each of the pediatricians received a recruitment package which included the 
inclusion criteria, a tracking form, and the parents’ package (Appendix G-H). The 
inclusion criteria specified that participants must meet all the requirements to be invited 
into the study (Figure 2.1). Learning disabilities or academic difficulties could be as mild 
as “pathway 2” in school. Behavioural abnormalities included but were not limited to a 
diagnosis of attention deficit disorder (ADD) or aggressive behaviours.  
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Figure 2.1 – Inclusion criteria for Janeway cohort. *Nonsyndromic refers to a boy 
who did not appear syndromic as judged by the developmental paediatrician.  
 
The tracking form recorded which criteria were met and allowed the researcher to 
track the number of patients being seen who did not meet the criteria. Once the 
pediatrician assessed that the child was eligible, the parent was invited to take an 
information package. The parent package included a letter explaining the study, the 
consent form with special DNA consent form attached, a stamped return envelope and a 
blood requisition form (Appendix I).  
* Nonsyndromic boys 
 (ages 3-18) 
2 of the 4 
criteria 
Speech delay requiring 
speech therapy 
Learning disabilities or 
academic difficulties 
requiring alternative school 
programming 
Behavioural abnormalities  
necessitiating input from a 
behaviour managment or 
child management specialist  
IQ testing that shows 
borderline (IQ = 70-80) or 
mild (IQ  = 50-70) ID 
will not be 
referred to 
Medical 
Genetics 
having blood 
drawn 
no known 
etiology 
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2.1.3.3 Consent Process  
Once a blood sample was received, the parent was then contacted to explain the 
study in more detail. Although providing a blood sample implied consent, like the 
retrospective study, a signed consent from the parent was needed before FRAXE testing 
could be conducted. If a signed consent was not received within several weeks of 
receiving the blood sample, the parent was re-contacted and reminded if the family was 
still willing to participate, a signed consent would need to be received before testing 
could proceed. 
 
2.1.4 Controls 
Two hundred and eighty males from Newfoundland who were previously 
recruited through random-digit-dialing as the controls for a colorectal cancer (CRC) 
study
120
, were used as the control population. When these Newfoundlanders were 
recruited as CRC study controls, they were not asked specific questions about their 
intellectual or academical abilities. However, they all completed a detailed enrolment 
package which implies that they could all read and write. The package included a consent 
form, a family history questionnaire, a personal history questionnaire and a food 
frequency questionnaire. All CRC control samples tested were anonymized and hence 
could not be linked back to the individual person. This process was approved by 
Memorial University’s Research Ethics Board [05.175]. 
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2.1.5 FMR2 Test Results 
Once FMR2 testing was complete, parents were notified of the result. If the test 
result was negative, the mutation report along with a letter explaining the result was sent 
to the parent (Appendix J-K). A copy of the test result was also sent to the referring 
doctor. If the result was positive, the parent was contacted and invited to come into the 
genetics clinic to speak with a geneticist.  
 
2.1.5.1 Positive FMR2 result 
Individuals found to carry a FMR2 expansion were invited to come into the 
PMGP to meet with a geneticist and discuss the result. The option was made available for 
confirmation of the result at the molecular diagnostic lab at the Hospital for Sick Children 
in Toronto. If the parent(s) agreed, the affected child had a clinical examination to 
identify possible dysmorphic features which included growth parameters, facial 
measurements and a clinical photograph. IQ testing was offered by a trained psychologist 
and the medical chart was reviewed. Additional family members were given the option of 
having FMR2 testing (beginning with the male proband’s mother) and if a premutation or 
full mutation was identified, that relative was offered the same evaluation as the proband. 
In addition, genetic counselling was offered to the family. Recurrence risks were 
discussed in relation to the probands’ parents and other family members and for the 
proband if he ever decided to have children.  
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2.1.6 Literature Review 
All papers describing FRAXE positive cases were catalogued by using search 
terms “FRAXE” and/or “FMR2” and/or “FMR-2” in Reference Manager. The abstract 
was reviewed and the paper obtained if a FRAXE mutation had been found or the FMR2 
gene had been investigated. Papers were divided into two categories – FMR2 case reports 
and FMR2 screening studies.  
 
2.1.6.1 Case Reports 
For the case reports all individuals who tested positive for a FRAXE mutation 
were recorded. All phenotypic features were noted in an excel spreadsheet and divided 
into categories and sub-headings. The phenotypic features extracted from the publications 
were reviewed by a clinical geneticist (BF) who combined some of these, where 
appropriate. The number of positive cases of males versus females in each family was 
recorded.  
 
2.1.6.2 FMR2 Screening Reports 
For the studies evaluating FMR2 status in various cohorts the following was 
recorded in an Excel spreadsheet: the number of alleles (or in some cases the number of 
participants), the proportion of individuals in each FMR2 expansion class (normal, 
intermediate, premutation and mutation) and the geographical origin of the study subjects. 
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The minimum, maximum and mode allele sizes were also noted when available. This 
information was also recorded for the control population. 
2.2 Molecular Analysis 
 
2.2.1 DNA Extraction from Blood 
Five volumes of warm Red Cell Lysis Buffer (0.14 M NH4Cl, 0.017 M tris pH 
7.65) solution were added to 1 volume blood in a 50 ml centrifuge tube. The tubes were 
centrifuged at 2500 rpm for 5 minutes. The supernatant was discarded leaving a white cell 
pellet at the bottom. Ten ml of 0.15 M sodium chloride saline was added to the tube, 
vortexed and centrifuged at 2500 rpm for 5 minutes. The supernatant was removed and 3 
ml of Nuclei Lysis Buffer (10 mM Tris, 400 mM NaCl, 2 mM EDTA) was added to the 
cell pellet. The mixture was vortexed and transferred into a 15 ml centrifuge tube. 0.25 ml 
of 10% SDS and 0.6 ml of pronase E solution (3 mg/ml in 1% SDS, 2 mM EDTA) was 
added and the mixture was incubated in a 37
o
C water bath overnight. Once removed from 
the water bath, 1 ml of saturated NaCl was added, shook vigorously for 15 seconds and 
centrifuged at 2700 rpm for 17 minutes. The supernatant was poured into a 15 ml tube 
containing 2 volumes of absolute ethanol (EtOH) and inverted several times. The DNA 
strands were hooked out and washed several times with streams of 70% EtOH. The DNA 
was air dried, placed in a 1.5 ml tube and dissolved in 200 µl of TE (10 mM Tris, 1 mM 
EDTA, pH 8). DNA was dissolved overnight and then put on a spinning rotator for 1 hour 
to ensure complete rehydration. Samples were then quantified by UV spectrometry. 
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2.2.2 PCR-based FMR2 Expansion Testing 
DNA samples which had been collected previously were retrieved from the 
Laboratory Medicine DNA Bank. Each DNA sample was mixed with 0.5 µl of 25 
pmol/µl of primers 598 (fluorescent labelled) and 603 (Appendix L – Supplementary 
Table S.2), 0.5 µl of Amplitaq (Applied Biosystems) and 11.5 µl of Fragile X Buffer. 
Fragile X buffer contained 400 µl of 10X buffer II (Applied Biosystems), 240 µl of 25 
mM MgCl2, 8 µl of 100 mM deoxyadenosine triphosphate (dATP), deoxycytsosine 
triphosphate (dCTP) and deoxythymidine triphosphate (dTTP), 160 µl of 5 mM 7-deaza 
guanosine triphosphate (GTP), 400 µl of DMSO, 800 µl of Betaine and 1058 µl of 
ddH2O. Samples were amplified in the thermocycler under the following conditions: 5 
minutes at 95°C for initial denaturation, 55°C for 25 seconds, 72°C for 25 seconds, 
followed by 30 cycles of 95°C for 45 seconds, 65°C for 30 seconds and 72°C for 30 
seconds, with a final elongation of 72°C for 10 minutes with a 15°C hold (Protocol from 
the Hospital for Sick Children, Toronto, personal communication). Amplicons were 
stored at 4°C until they were visualized on an agarose gel stained with Ethidium bromide 
using UV light. Samples which did not produce an amplicon were repeated and if a 
second PCR analysis produced no product, the sample was sent for Southern blotting 
analysis.  
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2.2.3 X and Y Chromosome Markers 
DXS990, DXS986, DXS1226, DXS1214, DXS8055 and DXS991 (Appendix L – 
Supplementary Table S.2), markers from the Applied Biosystems (ABI) Prism Linkage 
Mapping Set v2.5 were used. PCR conditions were carried out as follows: 1.0 µl of 100 
ng/µl of DNA was mixed with 0.75 µl of 10X PCR Buffer, 0.25 µl of 100 pmol/µl of 
forward and reverse primer, 0.1875 µl of 10 mM of dNTPs, 0.375 µl of 50 mM MgCl2, 
0.075 µl of Platinum Taq (Invitrogen) and 4.6125 µl of dH2O to make up a final volume 
of 7.5 µl. Samples were amplified in the thermocycler under the following conditions: 3 
minutes at 95°C for initial denaturation, 10 cycles of 94°C for 15 seconds, 55°C for 15 
seconds, 72°C for 30 seconds, followed by 20 cycles of 89°C for 15 seconds, 55°C for 15 
seconds and 72°C for 30 seconds, with a final elongation of 72°C for 10 minutes with a 
4°C hold. 
Y chromosome markers DYS570, DYS643 and DYS490
121
 (Appendix L – 
Supplementary Table S.2), were run using the same protocol.  
 
2.2.4 Fragment Analysis 
PCR products were diluted to 1 in 15 ratio with deionized water (dH2O) and 1.2 µl 
of this diluted amplified PCR product was suspended in 8.3 µl of High-Di Formamide 
(ABI) and 0.5 µl of Liz500(-250) size standard using a 1:1:2 ratio based on which 
fluorescent label (blue: green: yellow) the marker was tagged with. Samples were 
denatured in the thermocycler for 2 minutes at 95°C and quickly cooled by immediately 
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placing on ice. Samples were run on the ABI 3130xl and analysed using ABI’s 
Genemapper software. 
 
2.2.4.1 FMR2 Genotype and Repeat Size 
To determine the size of the FMR2 repeat, samples were first binned using 
Genemapper software. A subsample of the genotypes were viewed graphically to see 
where they fell on the X-axis and anything that fell within +/-0.7 was represented by the 
same value. Once all samples were binned, FMR2 repeat size was determined by 
subtracting the PCR amplicon size minus the repeat (290 bp) and dividing by 3 (Figure 
2.2). Results were verified independently to ensure accuracy. 
 
agctgtccaggctccgccccctgtgagtgtgtaagtgtgtgatgctgccgcggccgccgc 
cgccgcctgtgcagccgctgccgccgccgccgccgccgccgccgccgccgccgccgccgc 
cgccgctgccgccccggctgccgcgccgcgccgctgcctctgccccggccgcccccgccg 
ccgctgccgccgccggcccgcagccagccaggcgggcggcccagcccgcctgagcccgca 
gcggctgccgccgcagcgtcgggtcgctgggtgcgcgggctaccgcggaccgagcggacc 
cgagtgggcgaccaggcgcttgcccgcccagtgccactgccgccgcttcctcgccggagc 
 
Figure 2.2 - FMR2 PCR amplicon. Forward primer is colored in green, reverse primer is 
colored in purple and CCG repeat is highlighted in yellow. To determine repeat size, 
amplicon size was subtracted from 290 and divided by 3. 
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2.2.4.2 Comparison of FMR2 Allele Size in Test Population versus Controls 
The distribution of FMR2 allele size was compared between the test population 
from the retrospective study and the controls by tallying all repeat sizes for each allele 
size seen, dividing by the total and multiplying by 100 to get the percentage. A Fisher test 
was applied to determine if there was a significant difference seen between the two 
populations.   
 
2.4.4.3 Comparison of FMR2 Allele Size in the Newfoundland population versus the 
literature 
Based on the information collected from the literature review the minimum, 
maximum and mode FMR2 allele sizes were compared across all studies and compared 
with the sizes seen in the NL population.  
 
2.2.5 FMR2 Sequencing 
 
2.2.5.1 FMR2 PCR for Sequencing 
A subset of the samples was sequenced to confirm fragment size. PCR for 
sequencing followed the same protocol as described in section 2.2.2 except primers 598 
and 603 were not fluorescently labelled.  
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2.2.5.2 PCR Amplicon Purification 
Following amplification, excess nucleotides and primers were removed from the 
PCR amplicon by incubating with EXOSAP: a cocktail of 0.5 µl of exonuclease I (ExoI), 
0.5 µl of shrimp alkaline phosphatase (SAP) and 7.5 µl of dH2O were added to 8.0 µl of 
amplified PCR product and incubated in the thermocycler for 30 minutes at 37°C, 
followed by 15 minutes at 80°C.  
 
2.2.5.3 Sequencing Reaction 
1.0 µl of EXOSAP product was then added to 0.5 µl of sequencing mix (ABI), 2.0 
µl of sequencing buffer, 2.0 µl of 5 pmol/µl of primers 598 and 603 and 14.5 µl of dH2O. 
Samples were denatured for 1 minute at 96°C, followed by 25 cycles of 10 seconds at 
96°C, 5 seconds at 50°C, 4 minutes at 60°C. The cycle sequencing reaction was stopped 
with the addition of 5.0 µl of EDTA. 
 
2.2.5.4 Sequencing Amplicon Purification 
Immediately following the addition of EDTA, 65µl of 95% EtOH was added and 
the samples vortexed to allow the DNA to precipitate out of solution. Samples were 
placed in the dark for 1 hour up to overnight. After precipitation, the sample plate was 
centrifuged for 30 minutes at 3000 g. Following the spin, the sample plate was inverted 
on paper towels to decant the ethanol. Samples were then washed with an additional 
165µl of 70% ethanol and centrifuged for 15 minutes at 3000g. Following the spin, the 
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plate was inverted to decant the ethanol and placed in the dark to allow the samples to 
dry. Once dried, the samples were resuspended in High-Di Formamide, vortexed and 
briefly spun and placed in the thermocycler to denature at 95°C for 2 minutes. Samples 
were immediately supercooled by placing on ice and run on a 3130xl ABI Sequencer. 
 
2.2.5.5 Sequencing Analysis 
All samples were run using the Sequencing Analysis program and imported into 
Sequencher to be visually compared to the reference sequence. FMR2 repeat size was 
manually determined by counting the number of CCG repeats in each sample and 
recorded in an excel spreadsheet. Results were read independently by two members of the 
research team to ensure accuracy.  
 
2.2.6 FMR2 Expansion and Methylation Testing 
 8 µg of DNA was sent to Human Genetik, a clinic laboratory in Germany for 
FMR2 expansion testing on several members from Family A (IV-1, III-2, III-6, III-8) (see 
Figure 3.1 for pedigree) and from the proband of Family C (III-1); these were the two 
families that had consented at the time of testing. A control sample (C50), a retrospective 
sample (12273), and a Janeway sample (364), that were inconclusive using PCR-based 
FMR2 testing, were also sent for further investigation.  
 During the course of this work, a research laboratory in Chicago, Rush University 
Medical Center, started offering both expansion and methylation testing for FMR2. As the 
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results from Human Genetik were inconclusive for some of the samples and this research 
facility also provided methylation results, the samples were sent there instead. 8µg of 
DNA was sent to Rush University Medical Center from members of Family A (IV-1, III-
2, III-6, III-8), from the proband for Family C (III-1), and the control sample (C50) (see 
Figure 3.1 for pedigree).  
 
2.3 Founder Effect Study 
 
2.3.1 KINNECT  
2.3.1.1 Data Mining 
Pedigrees were created in Progeny and relevant fields such as individual name, 
middle name, also known as, last name, maiden name, date of birth, place of birth and 
address were exported as a text file. Field headings between Progeny and KINNECT were 
matched before importing the data into KINNECT. For example, in Progeny, a female's 
last name was considered her last name at the time the data was collected, however, in 
KINNECT a female's last name was her maiden name and if the individual was married, 
that name was called the surname. Number format for date of birth and date of death were 
revised to be consistent. Gender was reformatted from male or female to 1 for male and 2 
for female. The additional information field in Progeny was reviewed and if it contained 
place of birth and/or current living location, this information was distributed under 
appropriate headings. Individuals in the pedigree were given a unique identifier. This 
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identifier was a combination of the pedigree number and the system ID number assigned 
by Progeny. All individuals born after 1945 or individuals with only a surname or first 
name were removed.  
 
2.3.1.2 Generation of KINNECT Results 
The families were analyzed using KINNECT
122
, and results viewed in an Excel 
spreadsheet. Each individual in Progeny who was found to have a significant match in the 
Newfoundland Genealogy Database (NGD) was given both an individual and family 
match score. Match scores were based on the number of fields matched as well as the 
family structure of the matched family in the NGD compared to the Progeny family. 
Results were sorted based on unique identifier, family score and individual score with 
highest ranking on top. Each record was checked using the unique NGD number, as 
families in the NGD were recorded by household and community, easily allowing one to 
determine if this individual match was to the correct family.  
Once a positive match was found, all the information for that family was added to 
the family file. The census data listed all members living in the household and the 
individual’s relationship to the head of the household. This allowed extended family 
members such as siblings, parents, in-laws, cousins, etc. to be recorded and family 
members who did not have a positive match but were in the NGD database.  
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2.3.1.3 Additional Genealogy Resources 
All families were researched using Stonepics, a collection of CDs which contain 
pictures of headstones in most graveyards in the province. Software to accompany 
Stonepics allows the user to search based on name, community and year of birth. If 
additional information about the family was found, it was added to the pedigree.  
Pedigree expansion was also explored using online resources. Genealogy 
databases such as ancestory.com and familysearch.org and more Newfoundland based 
websites such as Newfoundland Grand Banks (http://ngb.chebucto.org/) and the NL 
GenWeb (http://www.rootsweb.ancestry.com/~cannf/) were explored. Obituaries and 
birth announcements from local newspapers were searched. The population therapeutics 
research group (PTRG) had a number of additional online resources catalogued pertaining 
to Newfoundland genealogy such as books and/or online blogs describing large extended 
families in certain areas of the province which were created for public interest or for 
events such as local “Come Home” celebrations.  
The PTRG, through Memorandums of Understanding (MOUs) with various 
church denominations, had digital copies of church registers from across the province. 
These registers provided records of most births, marriages, and deaths within a 
community. This resource was used to help clarify parental information, dates of birth, 
and places of birth through baptismal records. It also helped to identify maiden names of 
females through marriage records.  
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2.3.2 Haplotype Analysis  
2.3.2.1 X chromosome markers for haplotype analysis 
Markers flanking the FMR2 gene were investigated using the Genome Browser 
Gateway on the UCSC Genome Bioinformatics website. DXS998, DXS7847, DSX7393, 
DXS7389, DXS7390, DXS7394, DXS7812, DXS1318, DXS6729, DXS8303, DXS1185, 
DXS457, DXS1123, DXS1215, DXS548, DXS533 and DXS1193 (Appendix L – 
Supplementary Table S.2), were chosen based on the proximity to the gene and their 
heterogeneity (Figure 2.3). PCR conditions were carried out as previously described in 
section 2.2.3 and amplicons were run on the ABI Sequencer as described in section 2.4. 
 
 
Figure 2.3 – Location of X chromosome markers in relation to the FMR2 gene for 
haplotype analysis. X chromosome makers flanking the FMR2 gene are highlighted in a 
yellow box. 
       ---------------- FMR2 Gene --------------- 
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2.3.2.2 Haplotypes 
Genotypes were analyzed and the distances of the markers from FMR2 were 
calculated using the UCSC (University of California, Santa Cruz) Genome Browser and 
plotted on the pedigree to create haplotypes in Progeny. Males were used to create 
haplotypes for the female parent. Haplotypes between families were compared to 
determine if they shared a common region. A control sample was tested to compare to the 
haplotypes seen in the families.  
 
2.3.3 FRAXE Prevalence in the Male Newfoundland Population 
For Newfoundland, the minimum prevalence of FRAXE in the pediatric 
population was calculated using the number of positive FRAXE boys known to be living 
in the province of NL divided by the total number of boys living in the province of NL 
between 2 and 18 years of age in 2011.  
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Chapter 3 - Results 
 
3.1 Participant Recruitment 
3.1.1 Families 
As stated in section 2.1.1, at the time this study was initiated, there were two 
families known to the Provincial Medical Genetics Program (PMGP) that were 
segregating FMR2 expansions and these families were consented to this study.  
Two additional families were referred to the PMGP from the genetic outreach 
clinic in Corner Brook during the course of the study. The genetic counsellor in that area 
explained the study to those two families in detail and they both agreed to participate in 
the project.  
 
3.1.1.1 Family A (known to PMGP prior to initiation of the study) 
The mother of the proband (III-2) of Family A gave permission to the genetic 
counsellor to be contacted about the FRAXE study and the study was explained in detail 
by the research team (Figure 3.1). The mother agreed to the study and came in for a 
follow-up appointment with a geneticist. The proband’s parents signed the consent form 
and additional blood samples were collected for CGH microarray analysis. As well, IQ 
testing was arranged for the proband and his mother who carried an FMR2 premutation. 
The proband’s mother spoke to her sisters regarding the study and determined that they 
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were willing to be contacted by the research team. The mother no longer had contact with 
her brothers. Individual III-6 (the proband’s maternal aunt) was contacted by phone and 
the study was explained in detail. She signed a consent and gave a blood sample for 
FMR2 testing. Individual III-8 (the proband’s maternal aunt) was previously seen at 
PMGP and was known to carry a FMR2 expansion, as did her son IV-7 (Figure 3.1). 
When contacted by a genetic counsellor, she gave permission for her banked DNA to be 
used, as well as her and her child's clinical records to be reviewed for research. She was 
not willing at that time to come into the clinic or provide additional samples.  
 
3.1.1.2 Family B (known to PMGP prior to initiation of the study) 
Unfortunately, no contact was made by the genetic counsellor with this family. A 
telephone message was left asking the family to call the PMGP. After two months of no 
return call, a letter was sent regarding a follow-up appointment for the child through the 
clinic, however, the family did not keep this appointment. Therefore, no further workup 
could be done on this family. 
 
3.1.1.3 Family D (identified by the PMGP following initiation of the study) 
The genetic counselor in the area contacted the family and obtained consent on 
behalf of the research team (Figure 3.1). Blood samples were obtained of the proband 
(III-1) and his premutation mother (II-2) for haplotype analysis. The maternal 
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grandmother (I-2) gave permission for the research team to use her banked DNA sample 
for this study.  
 
3.1.1.4 Family E (identified by the PMGP following initiation of the study) 
The genetic counsellor made contact with and obtained consented on behalf of the 
research team (Figure 3.1). As in the case with family D, the parents signed a consent 
form and blood samples were collected from the proband (IV-1) and his premutation 
mother (III-2). The maternal grandmother (II-2) and great-grandmother (I-2) also signed a 
consent form and gave permission for their banked DNA sample to be used for the 
research study.  
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Figure 3.1 – Pedigrees of Family A, D and E. Dark shading indicates an FMR2 
expansion; circle inside the symbol indicates a carrier female; red top right hand shading 
indicates infertility. The number inside the pedigree indicates the number of offspring, 
sex unspecified and a small diamond indicates miscarriage. The number under the sample 
ID indicates the FMR2 expansion allele size.  
 
Family A 
Family E Family D 
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3.1.2 Retrospective Cohort 
3.1.2.1 Eligible Participants 
A total of 357 patient charts were reviewed. Forty five percent (158/357) of 
individuals were invited into the study based on the inclusion criteria (described in 
section 2.1.2.1), and of these, 92 consented (Figure 3.2). 56% (199/357) of the charts 
reviewed were excluded because they did not meet the inclusion criteria. The majority of 
those excluded were individuals who were either female (94/199 [47%]) or boys who 
were already tested for FMR2 expansions (61/199 [31%]) and found to be negative.  
 
Figure 3.2 – Flow diagram of the charts reviewed for the retrospective study. The 
number of individuals within each category is shown in parentheses. *Other includes 
individuals that were excluded from the study due to special circumstances and did not fit 
any of the categories described.  
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Twelve percent (44/357) of individuals were excluded based on their age at the 
time of testing (outside of the included age range of 2 to 19 years), a molecular diagnosis 
to explain their phenotype or no FMR1 result present in the chart. Individuals in the latter 
group had a requisition for FMR1 expansion testing in their clinical chart, but no test 
result present. These included individuals whose parent(s) initially agreed to FMR1 
testing as part of the clinical genetic assessment, but did not provide a blood sample, as 
well as individuals for whom the initial FMR1 testing by the appropriate laboratory failed 
and an additional sample was not received by the clinic.  
Of the 158 boys eligible as indicated in Figure 3.2, 66 individuals were not 
enrolled in the study because they were lost to follow-up, no sample was available or a 
signed consent form was not received. An additional five individuals with special 
circumstances were excluded from the study: two children had died, one individual was 
living in a long-term care facility, and two individuals were brothers whose parents had 
indicated they wanted their children’s DNA samples destroyed after initial testing. As the 
inclusion criteria stated that a banked DNA sample must be available for testing, these 
individuals were not contacted.  
The parents/guardians of the remaining 92 males consented to participate in the 
study. The overall participation rate was 58.2% (92/158).  
 
3.1.2.2 Chart Review 
The reason for the child’s referral to genetics was indicated in 90 of the 92 male 
charts in the retrospective study (Table 3.1). The reason for referral was broken down 
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into four categories: 1) autism spectrum disorder (ASD), which included ASD, 
Asperger’s and pervasive development delay (PDD); 2) developmental delay, which 
included developmental delay, speech delay, mental/physical handicap, low IQ, cognitive 
delay, ADHD, large head/developmental delay, motor delay, seizures, and several 
syndromes associated with developmental delay and dysmorphism; 3) fragile X syndrome 
or other neuropsychiatric disorders which included psychosis and schizophrenia; and 4) 
dysmorphology/visible malformation, which included cleft lip palate, tremor and 
hemihypertrophy.  
Sixty percent of all individuals were referred because of developmental delay of 
unknown etiology, compared with only 7.8% where Fragile X syndrome genetic testing 
was specifically requested. Twenty three percent of individuals were referred because of 
confirmed or suspected ASD and 9% were referred for dysmorphic features.  
 
Table 3.1 – Reason for referral for 90 boys in the retrospective study 
 
Reason for Referral # (%) 
Autism 21/90 (23.3%) 
Developmental Delay 54/90 (60.0%) 
Possible Fragile X syndrome 7/90 (7.8%) 
Dysmorphology/Visible Malformation 8/90 (9.0%) 
Not available * 2/92 
* For two individuals, the reason for referral was not indicated in the genetics clinic chart. 
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A review of the genetic charts was completed on all 92 participants enrolled in the 
study. The mean age of these 92 boys at the time of the clinic genetic assessment through 
the PMGP was 7.82 years. Accounting for the 18 month to 2 year wait list to be seen by a 
geneticist during the study period, the majority of boys were at least 5 years old when 
referred for genetic consultation.  
As part of the consult, several assessments were carried out for each child and are 
summarized in Table 3.2. Eighty percent of children were sent for chromosomal analysis 
and 77% had a biochemical metabolic work up. For those for whom information was 
available, 45% were dysmorphic and 61% had a positive family history of developmental 
delay, ID or learning problems.  
 
Table 3.2 – Review of genetic charts for 92 consenting boys previously tested for 
FMR1 expansions with negative results 
 
 # Assessed (%) 
# with an Abnormal 
Value (%) 
Dysmorphology present 86/92 (93.5) 39/86 (45.3) 
Family History of DD and/or ID 
and/or LD 
77/92 (83.7) 47/77 (61.0) 
Head Circumference 61/92 (66.3) 27/61 (44.3) 
Height 68/92 (73.9) 15/68 (22.1) 
Head CT 53/92 (57.6) 5/53 (9.4) 
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 # Assessed (%) 
# with an Abnormal 
Value (%) 
EEG  51/92 (55.4) 11/51 (21.6) 
Biochemical/Metabolic 71/92 (77.2) 4/71 (5.6) 
Molecular Tests (excluding FRAXA) 13/92 (14.1) 0/13 (0) 
Chromosome Analysis 74/92 (80.4) 3/74 (4.1) 
Total 92  
The # assessed indicates the number of individuals that were evaluated for each of the 
headings divided by the total number of individuals included in the study; percentages in 
parentheses. Abnormal value indicates the number of individuals that had a test result that 
was abnormal on the test report or required a follow-up test divided by the total number 
of test results available. DD = developmental delay; ID = intellectual disability; LD = 
learning disability; CT = computerized tomography; EEG = electroencephalogram.  
 
3.1.3 Janeway Study 
Information was received on 17 boys who had been recruited into the FRAXE 
study through the Child Development Clinic, Janeway Children’s Health and 
Rehabilitation Center, St. John’s. Of these 17 boys, a signed consent form and blood 
sample was received for 14 individuals. Three individuals did not participate in the study 
for various reasons: a blood sample was received for one participant but the parent 
declined the study; another parent verbally agreed to participate but a signed consent form 
or blood sample were not received; and one parent received an information package from 
the physician, but contact was never made with the parent and no signed consent form or 
blood sample were not received.  
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 All individuals in this cohort whose parent(s) consented and provided a blood 
sample for their child were tested for FMR2 expansions. A mutation report, along with a 
letter explaining the result was sent to each parent and the referring pediatrician for the 
child's medical chart.  
 
3.1.4 Controls 
DNA was available from 528 individuals who were recruited as controls through 
random-digit-dialing for a study on colorectal cancer and who agreed to have their 
anonymous DNA samples used in other studies
120
. Of the 528 participants, only male 
participants were included of whom there were 284 (53.8%). Of the 284 male samples 
available, DNA was received on 277. Seven samples were unavailable due to DNA 
quantity and/or quality issues.  
 
3.2 Molecular Analysis 
 
3.2.1 PCR based FMR2 Testing 
All DNA samples from the PMGP retrospective (n=92), Janeway (n=14), and 
control cohort (n=277), as well as the additional family member (n=1) from the recruited 
FRAXE positive family (Family A) were amplified for FMR2 gene analysis and 
calculations were carried out to determine repeat sizes.  
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Of the 92 individuals meeting the inclusion criteria for the retrospective study, all 
samples were in the normal range except for 1 sample (03MG438), which failed to 
produce a visible amplicon. PCR for the FMR2 repeat for the Janeway cohort produced 
an amplicon for each of the 14 individuals enrolled in the study. In the control population, 
one sample (C50) failed to produce an amplicon. The aunt (III-6) of the proband in 
Family A produced a single allele. There were no intermediate or premutations seen in 
any of the samples tested. The retrospective sample (03MG438) and the control sample 
(C50) which failed to produce an amplicon underwent further testing, detailed in section 
3.2.2 (FMR2 expansion testing). 
 
3.2.1.1 Allele Sizes 
Allele size was determined using fragment analysis. Samples were binned and 
repeat size was determined as described in section 2.4.4.1. A subset of the samples, one 
for each repeat size observed, was sequenced. Fragment analysis size was off by 3 repeats 
to the actual repeat size observed in the sequencing data (Figure 3.3). The allele size seen 
in each of the cohorts is presented in Appendix L – Supplementary Tables S.3, S.4 and 
S.5. An FMR2 allele size was not obtained on all samples using PCR. A summary of the 
results for all three cohorts is presented in Table 3.3.  
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Table 3.3 – Summary of FMR2 results using fragment analysis for each of the 
cohorts 
Cohort # of Individuals 
FMR2 result 
obtained by PCR 
Retrospective  92 90 
Janeway 14 13 
Control 277 267 
     
 
 
 
Figure 3.3 – An example of an FMR2 result obtained for 1 sample using fragment 
analysis vs Sanger sequencing. Result obtained from fragment analysis was binned to 
299 indicating a repeat size of 3 compared with 6 repeats obtained using Sanger 
sequencing.  
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For a small number of samples in the retrospective, Janeway, and control cohort 
an anomaly was seen in the genotyping data - the samples looked like they were 
heterozygous (Figure 3.4). For each of these samples, the two alleles present were within 
one repeat of each other and the peaks looked to be present in equal amounts. For some of 
the samples, rerunning the plate on the ABI Sequencer or redoing the PCR with a lower 
concentration of DNA resulted in the heterozygote phenomenon disappearing. For one 
sample from the retrospective study, one sample from the Janeway study and eight 
samples from the control cohort repeating the PCR did not resolve the issue.  
 
 
 
   
 
Figure 3.4 – Fragment analysis view of typical FMR2 allele and heterozygote 
phenomenon 
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The two samples from the participant cohorts (retrospective and Janeway) were 
sent for further evaluation to confirm that only one allele was present. From the control 
cohort, the eiht samples were removed from the study. For individual III-6 from Family 
A, the aunt of the proband, a single allele was seen in GeneMapper. As it is not possible 
to tell from fragment analysis if this female was a homozygote or carried an expansion 
not detected by PCR, further investigation was required.  
     
3.2.1.2 FMR2 Repeat Range in the Newfoundland Population 
The most common allele size in both the retrospective study (n=92) and controls 
(n=277) in the NL population was 12 (Figure 3.5). The distribution of FMR2 alleles in 
the test population is very similar to the controls except the test population had two allele 
sizes (3 and 6) that were not seen in the controls; the smallest repeat in the test population 
was 3 compared with 8 in the controls. Using a Fisher test the minimal allele size (>10) 
was not found to be statistically significant in the at-risk population compared with the 
controls (p = 0.81). The highest repeat size seen in the test population was 27 compared 
with 29 in the controls. The most common allele size seen in the cases and controls in the 
NL population was 12 compared with a repeat size of 15 in previously published 
data29,30,46,89,100-110.  
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Figure 3.5 – Comparison of FMR2 repeat range in the retrospective cohort versus 
the control population in Newfoundland 
 
3.2.1.3 X and Y Chromosome Testing 
As discussed above, two samples failed to produce an amplicon – one sample 
from the PMGP retrospective (03MG438) study and one from the control (C50) cohort. 
One sample from the retrospective study (12273) and one sample from the Janeway study 
(364) had two allele sizes which looked like an artifact as the alleles where within one 
repeat of each other. In addition, one control sample (C49) produced two distinct 
fragment sizes (15, 22) for FMR2 (Figure 3.6).  
For each of the samples, a new aliquot of DNA was obtained and the testing was 
repeated with the same results seen. To rule out poor quality DNA the samples that failed 
to produce an amplicon for FMR2 testing were run using 6 X chromosome markers. As 
one would not expect to see two alleles for an X chromosome marker in a cohort that 
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consisted entirely of males, the control sample (C49) was also tested using these markers 
to determine if this result was something specific to the FMR2 gene (Table 3.4).  
 
 
Figure 3.6 – FMR2 fragment analysis result for control sample C49 
 
 
Table 3.4 – Fragment analysis testing using X chromosome markers on specific 
samples from retrospective, Janeway and control cohorts 
 
X 
Chromosome 
Markers 
03MG438 
(Retrospective 
Cohort) 
364 
(Janeway 
Cohort) 
C49 
(Control) 
C50 
(Control) 
DXS990 124 126 132 130 
DXS1226 295 289 301, 307 293 
DXS1214 288 296 288, 294 286 
DXS986 165 161 165 167 
DXS8055 316 314 316 316 
DXS991 330 326 330 326 
 
92 
 
 
 Amplification for all six X chromosome markers were seen in both the 
retrospective (03MG438) and control sample (C50) that failed to produce an amplicon for 
FMR2. This ruled out poor DNA quality as the possible explanation for lack of 
amplification for FMR2.  
Premutations and full mutations cannot be detected using this technique and 
therefore may be the reason why these samples failed to produce an amplicon. An 
alternative possibility is that there was a single nucleotide polymorphism (SNP) in either 
of the primers used for FMR2 testing causing the primer not to anneal. The samples were 
then sent to a clinical laboratory to determine their FMR2 status.  
As indicated above, control sample C49 was heterozygous for FMR2 as well as 
two out of the six additional X chromosome markers tested. A possible explanation for 
this is that there was a mix-up in the DNA and the sample was actually female. To 
exclude this possibility, the sample was genotyped for three Y chromosome markers 
which all amplified (Table 3.5). Therefore, it can be assumed this individual’s karyotype 
is 47, XXY, Klinefelter’s syndrome. 
 
Table 3.5 – Fragment analysis testing using Y chromosome markers on sample C49 
from the control cohort 
X 
Chromosome 
Markers 
C49          
(Control Cohort) 
DYS490 173 
DYS643 133 
DYS570 257 
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3.2.2 FMR2 Expansion Testing  
 
3.2.2.1 FMR2 Expansion Testing - First Diagnostic Laboratory 
As described in section 2.2.6 samples with possible FMR2 expansions (03MG438 
and C50) were sent to an outside clinic laboratory, Human Genetik, for expansion testing. 
The retrospective sample (12273) and the Janeway sample (364) which showed a 
heterozygous result within one repeat size were also sent for further investigation. The 
aunt of the proband from Family A (III-6) whose FMR2 result was a single allele was sent 
to confirm if she was indeed a homozygote or harboured an expansion not detected by 
PCR method. Additional family members from Family A (IV-1, III-2, III-8) were sent as 
positive controls (see section 3.3.1.1; Figure 3.8 for pedigree). The results received from 
the diagnostic laboratory are shown in Figure 3.7. 
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Figure 3.7 – FMR2 expansion testing using Southern blot on select samples from 
clinical laboratory. Legend ID – Sample 1 and 2 are normal male and female; sample 3 
is a knockout of the gene. The remaining samples are from Family A (III-6 aunt; III-8 
aunt; III-2 mother; IV-1 proband), Janeway sample (364), control sample (C50) and the 
retrospective samples (03MG438, 12273).  
 
The quality of the data received from the outside clinical laboratory was 
disappointing. A summary of the results can be seen below (Table 3.6). For samples 
12273 and 364 from the retrospective and Janeway study, respectively, the lab reported 
no pathogenic mutation. This was as expected as other samples that showed the same 
allelic pattern when repeated only resulted in one fragment size. These were the only two 
samples that a mutation report was received from the clinical laboratory.  
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For two of the samples, the proband from Family A (IV-1) and the control sample 
(C50), no signal was detected which they suggested was due to low quantity of DNA 
available. To provide a result a new aliquot for the sample would need to be sent. For the 
two test samples, 03MG438 and the aunt (III-6) from Family A the lab said star activity 
was present. This indicated that something present in the sample interfered with the 
digestion. These samples were extracted using standard salting out method which has 
been known to interfere with downstream applications. The lab however did not suggest 
that an additional clean up method would alleviate the problem.  
 
 
Table 3.6 - A summary of FMR2 expansion testing on select samples provided by an 
outside clinical laboratory (Humane Genetik) 
Cohort Sample ID Clinical Laboratory 
Testing Result 
Previous 
Testing 
Retrospective 
Cohort 
03MG438 Star activity N/A 
12273 Normal  
no pathogenic expansion 
N/A 
Janeway Cohort  364 Normal  
no pathogenic expansion 
N/A 
Family A IV-1 (proband) No signal ~ 620 repeats 
III-2 (mother) Star activity ~ 120 repeats 
III-6 (aunt) Star activity N/A 
III-8 (aunt) Star activity ~ 87 repeats 
Control C50 No signal N/A 
     Star activity refers to insufficient digestion of assay. N/A = not applicable. 
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3.2.2.2 FMR2 Expansion Testing – Second Diagnostic Laboratory 
During this time, a research laboratory in Chicago, Rush University Medical 
Center, offered both expansion and methylation testing for the FMR2 gene requiring the 
same amount of DNA the clinical laboratory in Germany needed for expansion testing 
only. As the amount of DNA available was limited and the test required 8 µg, it was 
determined in the best interest to preserve the valuable sample it would be sent to the 
Rush University Medical Center. All samples were sent to the research laboratory except 
for the two samples that were reported not to have a pathogenic expansion. A summary of 
the results received from Rush University Medical Center is shown below (Table 3.7). 
No Southern blot image was provided. As indicated in the table below sample 03MG438 
from the retrospective study was found to harbour an FMR2 expansion. 
 
Table 3.7 – A summary of FMR2 expansion and methylation testing on select 
samples provided by an outside research laboratory (Rush University Medical 
Center) 
Cohort Sample ID 
Mutation 
Status Methylation Status 
Retrospective 03MG438  
small 
full/premut.  
(~ 250) 
Eco RI site - <10% methylated 
Eag I site - 10% methylated 
Family A 
02MG693  
(IV-1) 
Proband full mutation 
Eco RI site - 80% fully methylated; 
20% partially unmethylated 
Eag I site - 20% fully methylated; 
80% partially unmethylated 
02MG693  
(III-2) 
Mother of 
Proband 
premutation  
(~70-80) 
unmethylated on active X 
non-random X- inactivation 
(Premutation allele active allele 70% 
cells) 
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Cohort Sample ID 
Mutation 
Status Methylation Status 
377  
(III-6) 
Aunt of 
Proband 
premutation  
(~ 80-100) 
unmethylated on active X 
non-random X- inactivation 
(Premutation allele active allele 60% 
cells) 
03MG1104  
(III-8) 
Aunt of 
Proband 
premutation  
(~60-70) 
unmethylated on active X 
random X-inactivation 50/50 
Control C50  
Normal 
(no 
pathogenic 
mutation) 
 
 
3.3 FRAXE Positive Families and Founder Effect  
 
3.3.1 Clinical Description of FRAXE positive Families 
As stated, at the time of this study two FRAXE expansion families were known to 
the PMGP and one of these families (Family A) consented to be a part of this research 
project. This retrospective cohort of less than 100 NL boys revealed another FRAXE 
positive family (Family C). While this study was in progress, two additional FRAXE 
positive families were referred to the PMGP and were invited into the research project 
(Family D and E). Below is a description of the four families that consented to research 
(Figure 3.8).  
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Figure 3.8 – Pedi  
of four FRAXE positive families in Newfoundland 
Figure 3.8 – Pedigrees of four FRAXE positive families in Newfoundland 
Family A 
Family C 
Family D Family E 
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3.3.1.1 Family A  
The proband (IV-1, Figure 3.8) was investigated at 3 years of age for congenital 
macrocephaly, hypotonia, developmental delay and unusual facial features. Routine 
chromosomal analysis revealed a fragile site at Xq27 in 7 of 22 lymphocyte metaphases; 
the lymphocytes were cultured in a standard way and not in folate deficient media. FMR1 
testing was normal, so FMR2 testing was arranged and revealed a full FMR2 expansion 
(~620 CGG repeats). Methylation testing showed 80% full methylation at the Eco RI site 
and 20% fully methylated at the Eag I site, with no DNA completely unmethylated. 
Genome-wide microarray analysis (Agilent’s 40k oligonucleotide array) failed to identify 
any pathogenic genomic deletions or duplications.  
The proband remained hypotonic until 4 years. He walked at 4 years and did not 
speak in sentences until 6 years. His academic curriculum was modified, with a criteria C 
designation for moderate-severe cognitive delay. At 15 years, the Wechsler Intelligence 
Scale for Children III (WISC-III) testing showed a standard IQ score of 40, with < 1
st
 
percentile ranks in all areas. His visual, motor, academic and cognitive skills were at a 
kindergarten level. When examined at 16.5 years, IV-1’s head circumference was 
60.75cm (>> +2SD) and he had several facial features reminiscent of Fragile X syndrome 
including large ears, a prominent chin and forehead and other dysmorphic findings 
including a high arched palate and a wide mouth with thick lips.  
When examined at 21 years, the proband had macrodolichocephaly with a head 
circumference of 61.2 cm (>> +2SD); height was 173.5 cm (20
th
 – 50th centile) and 
weight was 70.5 kg (50
th
 centile). He had male pattern baldness, bitemporal narrowing 
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and prominent supraorbital ridges. He had brilliant green iridies with long palpebral 
fissures and ocular hypertelorism; inner canthal distance (ICD) was 6.4cm (well above +2SD). 
He had a wide mouth with thick lips and a high arched palate. His four upper incisors were wide 
spaced. Palmar creases, hand length and genitalia were all normal. As an additional measure, a 
higher resolution microarray was performed in a diagnostic laboratory and the proband was found 
to carry a heterozygous deletion of the 1p36.33 region. The deletion was also present in his 
healthy father and is most likely a benign copy number variant. 
During this time, an intellectual assessment was done using the Wechsler Adult 
Intelligence Scale (WAIS-III). The proband’s full scale score was IQ 54, which places 
him in the mild (bordering on moderate) intellectual disability (ID) range. There was no 
difference between the verbal and performance IQ (58). The subtest scale scores indicated 
his strengths are mainly in the nonverbal/visual areas and he was very weak in the area of 
verbal skills. At present, he can be left home alone and can operate an all-terrain vehicle 
(ATV) which he uses when hunting rabbits.  
The proband’s mother (III-2) carried a premutation of approximately 120 repeats. 
Methylation analysis revealed the FMR2 site was unmethylated and that there was non-
random X inactivation. The premutation allele was active in 70% of the cells, whereas the 
normal allele was active in 30% of the cells. When examined at 49 years, she had 
borderline large ears and a wide mouth and otherwise non-dysmorphic. She did not 
complete high school for social reasons, but did not have a history of academic difficulty. 
Her full-scale IQ score was 84. There was significant discrepancy between her verbal 
comprehension score (74) and her process speed scores (108) indicating that her visual 
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processing skills were better developed than her verbal reasoning skills and verbal 
conceptualization skills. She was employed as a home support worker.  
The proband’s mother (III-2) had two other sons (IV-2, IV-3) who inherited the 
normally sized allele from her. IV-2 was 26 years old at the time of the proband’s second 
assessment (at age 21 years). His curriculum was modified at school but he graduated 
from high school. The proband’s other brother (IV-3) was 29 years old at the time of the 
proband’s second assessment. His mother reported that he was behind in school in the 
early years but did graduate from high school with an A average and completed some 
post-secondary education.  
The proband’s mother (III-2) has three sisters, two of whom (III-6 and III-8) carry 
premutations. III-6 (age 50 years at the time of testing) had a premutation of 
approximately 80-100 repeats, which was unmethylated. This premutation was identified 
through this study. The premutation allele was the active allele in 60% of the 
lymphocytes tested on her blood sample. III-6 reported that she was unable to have 
children. She worked as a homecare worker with handicapped children.  
The proband’s mother’s other sister (III-8, age 40) also had a premutation of 
approximately 60-70 repeats which was unmethylated. Random X-inactivation was 
observed. III-8 has two children, one of whom (IV-7, age 21) had a small full mutation 
(~287 repeats). He had academic difficulty but finished high school and was employed as 
a laborer away from home. He was not available for examination or further assessment.  
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3.3.1.2 Family B 
 This family did not consent to research and therefore no clinical information is 
available.  
3.3.1.3 Family C 
This proband (III-1, Figure 3.8) was diagnosed with FRAXE through this study. 
He was originally referred for genetic consultation at age 7½ years because his biological 
mother had neurofibromatosis type 1 (NF1). III-1 has no cutaneous features of NF1 and 
his family was counseled that he was unaffected. At the time, FMR1 testing and routine 
chromosome analysis was performed because of academic difficulty. No X chromosome 
fragile site was identified on standard chromosome analysis. He was not tested for an 
FMR2 expansion at the time of the initial clinical assessment.  
He was tested for FMR2 because he fit the criteria for the retrospective part of the 
study which included male sex; referred to genetics with development delay; received 
FMR1 testing and remained without a specific genetic diagnosis. FMR2 testing revealed a 
250 repeat which was mostly unmethylated. Chromosome analysis using a folate-
deficient medium showed a fragile site at Xq27.3 in 5/60 metaphases (8%). CGH 
microarray analysis was normal. 
At the time of the initial genetic consult (age 7 ½ years old), the parent reported 
that he could count to ten, but could not read well. He could print his name at the 
kindergarten level and was in a modified curriculum at school. He had a few minor 
physical anomalies (mild brachycephaly, borderline low set ears and mild clinodactyly of 
the 5
th
 digits) but was not strikingly dysmorphic. He also had congentially fused left 
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fourth and fifth metatarsals. A detailed family history was not available; however, it was 
noted that his biological mother did not finish high school and was said to be a poor 
reader.  
During the first 11 years of life, III-1 had poor home circumstances. The medical 
geneticist reviewed an educational assessment from the school which was done at the end 
of his grade 6 year (June 2008, age 12 years). The assessment indicated that he was 
having academic difficulty with all subjects with the exception of Health and Social 
Studies. He received pathways 2 and 4 support. The pathway 4 support included an 
alternate course in literacy skills, provided by the special education teacher.  Pathway 2 is 
the provincially prescribed curriculum with student specific strategies and supports, 
whereas Pathway 4 is a combination of the core curriculum and individually designed 
curriculum to meet the student’s individual needs.  
At the age of 12 (grade 7), the Wechsler Individual Achievement Test (WIAT-II) 
was administered showing a total score of 71 (3
rd
 centile rank), with math reasoning skills 
at the 10
th
 centile, spelling at the 3
rd
 centile and written expression at the 5
th
 centile. 
Written spelling was at a grade 3.7 equivalent.  
When the proband was examined at 12 years, height was 159 cm (50-75
th
 centile), 
weight was 70.3 kg (97
th
 centile) and head circumference was 56 cm (+1.5 SD). He had 
some mild dysmorphic features including mild brachycephaly, borderline ocular 
hypertelorism with epicanthal folds and hooded eyelids, deep-set nails and slightly low-
set ears with thick, fleshy lobules. According to his case worker, he had some aboriginal 
ancestry and he was not considered to be strikingly dysmorphic by the geneticist. 
104 
 
 
The proband had his left 5
th
 ray amputated because of foot pain. He also had a 
tonsillectomy and nasal cauterization for recurrent nose bleeds. He was seen by a 
neurologist who diagnosed him with simple motor tics that included head flicking.  
The proband’s case worker described him has having a fairly good attention span 
and noted improvements in his reading skills since receiving tutoring. At this time of 
assessment, the boy was living in a group home and still had some academic difficulty.  
The proband’s sister (III-2) who also had academic difficulty carried an FMR2 
expansion of 750 repeats. Her initial chromosome analysis was normal at the 500 band 
level. Testing using a folate deficient medium showed an Xq27.2 fragile sit in 7/20 
metaphases (35%). III-2 also had a genome-wide microarray (Agilent’s Oligonucleotide 
Array, EmArray Cyto6000 Custom Design) which showed normal DNA copy number. 
She was assessed at age 14 ½ years and was also following a modified curriculum 
at school. Her teachers reported significant improvements in her reading since receiving 
additional support. She attended speech therapy as a child. On examination at 14½ years, 
the proband’s sister’s height was 159 cm (25-50th centile), weight was 53 kg (50th 
centile), and head circumference was 55.4 cm (+1SD). She was not dysmorphic. A short 
philtrum was noted (length 1.2 cm, slightly less than the 3
rd
 centile). There were no 
cutaneous findings of NF1.  
An EEG showed diffuse slowing of background waveforms on EEG. Overall, she 
was very articulate and her academic difficulty had improved significantly since her home 
environment stabilized. 
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3.3.1.4 Family D  
This 10 year old boy (III-1, Figure 3.8) was seen in the genetic clinic with his 
sister (III-2) who was referred because of a family history of multiple endocrine neoplasia 
type 1 (MEN1). Genetic testing for FMR1 and FMR2 was ordered for this boy because 
the genetic counsellor noted a history of mild learning difficulties in school. He had a full 
FMR2 mutation of 286 repeats. He walked independently at 18 months and had speech 
therapy due to a speech delay. At age 10 years, all classes were in a special education 
stream and there were no behavioural difficulties.  
When examined at age 10 years, the proband’s height was at the 25th centile, 
weight at the 10
th
 centile and head circumference was at the 10
th
 centile. He had triangular 
facies. He was mildly dysmorphic with protruding ears, partial syndactyly of the second 
and third toe. He had right cryptorchidism.  
The proband’s mother (II-2, age 37) had a premutation of 86 repeats. She reported 
struggling academically and needing additional support with reading. The proband’s 
sister (III-2, 13) also carried a premutation allele, with a repeat size of 186. The mother 
reported her daughter (III-2) had some difficulties with reading. The grandmother (I-2) 
was tested and found to have two normal FMR2 alleles. One would expect that the mother 
had inherited the FMR2 mutated allele from her father; however, there was no contact 
with this side of the family so further testing was not possible.  
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3.3.1.5 Family E 
This male proband (IV-1, Figure 3.8) was referred to genetics at 3.5 months of 
age because of a petechial rash, decreased platelets and anemia. At birth, he had no 
spontaneous respirations for two minutes and was intubated shortly after delivery. 
APGAR scores were 4 at 1 minute, 8 at 5 minutes and 8 at 10 minutes. In the neonatal 
period, an echocardiogram (ECG) revealed cardiac enlargement and a head CT showed 
an ill-defined hypodense area in the right occipital region consistent with ischemia. Both 
tests were normal when they were repeated. He was assessed by a clinical geneticist and 
no genetic testing was felt to be necessary at the time. 
The proband reached his early childhood developmental milestones on time. He 
used single words at 12 months, crawled at 8 months and walked independently at 15 
months. By three years his vocabulary was described as advanced for his age.  
At age twelve years, the proband was seen again in the genetics clinic because his 
maternal aunt (III-5, 39 yrs) had a routine chromosome analysis prior to in vitro 
fertilization (IVF) that showed a Xq fragile site. The proband had FMR2 testing which 
showed mosaicism for a full mutation with sizes of approximately 300 and 420 repeats.  
At 11 years, the proband had IQ testing. A Wechsler Intelligence Scale for 
Children IV (WISC-IV) was administered and full scale IQ was 96 (39
th
 centile – normal 
range). There was a significant discrepancy seen between his verbal comprehension score 
(108) and processing speed score (75). During the psychometric testing, he was noted to 
be highly active, moving in his chair and walking around the room constantly. The 
examiner concurred with his parents and teachers and suspected higher intelligence given 
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his strong verbal skills, abstract reasoning and creative ideas. This was supported by the 
Woodcock Johnson test of Cognitive Abilities III in which he scored in the superior range 
for verbal ability (121–92th centile) and comprehensive knowledge (121–92th centile). The 
examiner noted the testing scores would be minimums as he was highly unfocussed 
during the exam and felt that his true ability was potentially even higher. The examiner 
also noted some obsessive-like thoughts/behaviours and some unusual vocalizations.  
At age 13 years, the proband was diagnosed with attention deficit disorder (ADD), 
inattentive type. He had long standing attentional difficulties at school and was on a 
stimulant medication. Printing skills were messy and he was unable to perform cursive 
writing. He used a voice recognition system to do homework, but followed a regular 
curriculum with a 70’s average. Although he preferred to socialize with adults, there were 
no behavioural or social concerns.  
On physical exam at age 13 years, he was considered to be non-dysmorphic. The 
proband’s height was 164 cm (50th centile), weight 61.3 kg (75th centile) and head 
circumference was 59 cm (+3SD). He had sandy blonde hair, green irides and triangular 
facies with a somewhat low frontal hairline. His eyes were normally placed with a normal 
well developed philtrum. His mouth was small and he had a wide space between his 
upper central incisors, with minor dental malocclusion. His ears were normal in position 
and contour. There was no abnormality of the feet and hands. Palmar creases were normal 
and there was no clinodactyly of the digits. He had hyperextension of the elbows 
particularly of the left, with cubitus valgus. He had axillary hair, normal genitalia (Tanner 
stage 5) and there was no macroorchidism.  
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The proband’s mother (III-2) carried a full mutation of approximately 950 repeats. 
She had two additional children who did not have any learning problems and were not 
tested for FMR2 expansions.  
The mother (III-2) was hyperactive as a child, but did not have academic difficulty 
and has several years of post-secondary training. On examination at age 39, height was 
158 cm (10-25
th
 centile), weight was 66.9 kg (75
th
 centile) and head circumference was 
58 cm (+2SD). She was not dysmorphic.  
The proband’s maternal aunt (III-5) who had the cytogenetic fragile site, had a 
mosaic FMR2 expansion with allele sizes ranging from 400-700 repeats. Her 
chromosome analysis was ordered as part of work-up for infertility, prior to undergoing in 
vitro fertilization (IVF). She had no academic difficulty and had post-secondary 
education.  
The proband’s grandmother (II-2) had a premutation of 120 repeats and the great-
grandmother (I-2) had a premutation of approximately 86 repeats.  
In the literature FRAXE is described as being characterized by mild (IQ 50-69) to 
borderline (IQ 70-79) ID, learning problems, communication problems and overactivity, 
with no consistent dysmorphic features
36
. A summary of the male probands identified in 
the Newfoundland population with reference to the FRAXE phenotype description is 
provided in Table 3.8. 
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Table 3.8 – Summary of male probands from each of the four Newfoundland 
families with reference to the FRAXE phenotype description 
 Family A 
IV-1 
Family C 
III-1 
Family D 
III-1 
Family E 
IV-1 
FMR2 repeat size 
620 repeats 250 repeats 286 repeats 
300-420 
repeats 
Cognitive ability FSIQ - 54 FSIQ -71 *N/A FSIQ – 96 
Learning problems Yes Yes Yes Yes 
Speech Delay Yes Yes Yes No 
Attention problems No Yes Yes (ADD) Yes (ADD) 
Tic disorder No No Yes No 
Presence of 
Dysmorphology 
Yes (like 
FRAXA) 
Minor 
dysmorphism 
Minor 
dysmorphism 
No 
*No formal IQ testing. Clinically, he appeared to have mild ID (early milestones delayed 
and at the age of 10 years, alternate curriculum at school). ADD = formal diagnosis of 
Attention Deficit Disorder 
 
 
Consistent with previously published data, the probands in this study had 
inconsistent dysmorphology. Proband IV-1 from Family A was dysmorphic with physical 
features highly reminiscent of Fragile X syndrome (FMR1 testing was normal). He had a 
long forehead, prominent chin and large ears, high arched palate and macrocephaly which 
are common features seen in patients with Fragile X syndrome due to FMR1 expansion 
mutations. Proband III-1 from Family C had minor dysmorphism including mild 
brachycephaly, borderline low set ears and mild clinodactyly of the 5
th
 digits. Proband III-
1 from Family D also had very mild dysmorphism with protruding ears, mild syndactyly 
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of the second and third toes and right cryptorchidism. Proband IV-1 from Family E was 
not dysmorphic. 
IQ testing was only available on three out of the four probands. One male (IV-1 
from Family E) had an IQ within the normal range (FSIQ-96). A second male had a 
borderline low IQ (III-1 from Family C, FSIQ-71). The proband from Family A had mild 
ID (FSIQ-54) and had a more severe phenotype than the other three probands. Learning 
problems were seen in all four probands even though the degree of disability and extra 
help needed was variable. Speech delay was seen in each of the probands except IV-1 
from Family E. Attention problems were seen in all probands except IV-1 from Family A, 
and two probands were diagnosed formally with ADD.  
 
Table 3.9 – Summary of full mutation males, full expansion females and 
premutation females identified in the Newfoundland population 
 
 Full mutation 
males 
Full expansion 
females 
Premutation females 
Family A 
IV-1 (~ 620 repeats)  III-2 (~ 120 repeats) 
 
IV-7 (287 repeats)  III-6 (~ 80-100 repeats) 
 
  III-8 (~87 repeats) 
Family B* 
Full expansion   
Family C 
III-1 (~250 repeats) III-2 (~750 repeats)  
Family D 
III-1 (286 repeats)  III-2 (~186 repeats) 
 
  II-2 (~ 86 repeats) 
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Family E IV-1 (~300, 420 
repeats) 
III-2 (~950 repeats) II-2 (120 repeats) 
 
 
III-5 (~400-700 
repeats) 
I-2 (~ 86 repeats) 
Total 
6 3 7 
*Family B did not consent to research but proband was known to PMGP to carry a 
full FMR2 expansion.  
 
3.4 Founder Effect study 
 
3.4.1 KINNECT  
Expansion of the families focused on the side of the family that the disease was 
passing through; if this information was unknown, both sides of the family were 
investigated. Connections were made in the Newfoundland Genealogy Database (NGD) 
and this allowed families A and D to be expanded to 4-6 generations before the proband. 
A summary of the pedigree expansion for all families is shown in Table 3.10 below. The 
expanded pedigrees can be found in the appendix (Appendix M). Using the NGD, a 
common ancestor was not found in any of these families. 
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Table 3.10 – Number of individuals in each of the four FRAXE pedigrees before and 
after running through KINNECT 
 
Pedigree Original 
After 
KINNECT 
Additional 
Family 
Members 
Family A 43 114 71 
Family C 61 61 0 
Family D 26 117 91 
Family E 42 55 13 
 
3.4.2 Haplotype Analysis 
The proband and any additional family members whose DNA was available were 
haplotyped using 15/17 markers flanking FMR2 to help determine if a common ancestor 
connected these families. Of those 15 markers, only 7 markers were informative. From 
these seven markers, there is strong evidence that families A, C and D are related as they 
share a common haplotype of 1.88 Mb. To further support this theory, three generations 
of Family D were tested and the grandmother (I-2) who did not give the FMR2 expansion 
allele to her daughter (II-2) was shown not to have the disease haplotype. 
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Figure 3.9 – Haplotyped pedigrees of four FRAXE positive families in 
Newfoundland 
Family A 
Family C 
Family D 
Family E 
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3.4.3 Prevalence Rate  
 For Newfoundland, the minimum prevalence of FRAXE in the male pediatric 
population (2 to 18 years old) was calculated to be 6 males in 46,420, or 1 in 7,736. The 
minimum prevalence of FRAXE in the total male population was calculated to be 6 males 
in 251,901 or 1 in 41,983. The minimum prevalence of expanded FMR2 alleles in the 
Newfoundland population was calculated to be 16 in 512,900 or 1 in 32,056.  
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Chapter 4 - Discussion 
 
Brief summary: 
The purpose of this study was to determine the prevalence of FRAXE among boys 
referred to the Provincial Medical Genetics Program (PMGP) for intellectual disability 
(ID) and/or developmental delay. FRAXE is exceedingly rare in most populations with a 
prevalence rate of 1:23,423 males or 0.004%
34
. Because two FRAXE families were 
known to the PMGP, we hypothesized that FRAXE expansions might be present in 
additional Newfoundland and Labrador (NL) families with an overall population 
prevalence that is higher than in the general population. In a cohort of 92 boys referred 
for developmental delay with negative FMR1 results, one male (1.2%) was found to carry 
an FMR2 expansion. During the length of this study, two additional families became 
known to the PMGP. In the province of a little over 500,000 people, five Newfoundland 
families are now known to carry FMR2 expansions (three families ascertained through 
PMGP that participated in the research study, one family ascertained through PMGP that 
did not participate in the research project and one family ascertained through the 
retrospective cohort). The minimum prevalence rate calculated in the male pediatric 
population in Newfoundland was 1 in 7,736 or 0.01%. 
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4.1 Study Design 
 
4.1.1 Inclusion criteria  
As the vast majority of Fragile X testing (for FMR1 expansions) in the PMGP at 
the time was done on pediatric males, this study included boys between the ages of 2 and 
19 years at the time of FMR1 testing. The inclusion criteria for this study were very 
similar to what has been reported in the literature. Most research groups investigating 
FMR2 targeted individuals with developmental delay and/or ID
31,80-84,102,106-108,123-129
. 
Several studies looked at males and females with negative FMR1 testing in combination 
with developmental delay and/or ID
79,109,124,130
, which more closely matched the inclusion 
criteria for this study. Other reports in the literature were of children with academic 
difficulties and/or who attended special needs classes
30,34,46,100,104
. Cohorts with other 
phenotypes have also been screened and these phenotypes included autism spectrum 
disorder (ASD), Parkinson disease (PD), obsessive compulsive disorder (OCD) and 
premature ovarian failure (POF)
29,32,39,47,85,110,131
. Although including individuals from 
these types of broader cohorts was beyond the scope of this project, it is interesting to 
note that one female from Family E (III-5) was identified when a routine karyotype was 
ordered as part of an infertility work up. This showed an Xq27 fragile site which turned 
out to be due to a mosaic FMR2 full mutation (400-700 repeats).  
The retrospective ID cohort from the PMGP consisted of boys with severe enough 
phenotypes to warrant a clinical genetic assessment. In an effort to mitigate the 
aforementioned potential limitation and to enrich our chances of findings FMR2 
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expansions, a second cohort was investigated. These were boys assessed through the 
Child Development clinic at the Janeway Children’s Health and Rehabilitation Center for 
speech delay, learning disabilities or academic difficulties, behavioural abnormalities 
and/or borderline (IQ = 70-80) or mild (IQ 50-70) ID (see section 2.1.3.2 for inclusion 
criteria). Many of the children seen at Child Development have milder phenotypes and 
therefore would not necessary be referred to the PMGP, particularly if the developmental 
paediatrician considered the child to be non-dysmorphic. 
 
4.1.2 Male preponderance  
The chart review for the retrospective study found that of children referred for 
development delay during the ten-year period (1994-2004), 73.7% (263/357) were male. 
This finding was consistent with boys being more likely to present to their family 
physician with developmental delay, ID and/or learning disability. In the literature, it has 
been reported that 30% more males are diagnosed with ID than females
132
. In 2001, 
Statistics Canada produced a report that profiled disability in Canadian children and 
reported that males were more likely to have a speech-related disability than females 
(46.6% males compared with 37.6% females) and that boys were more likely to be 
diagnosed with a learning disability than girls (68.9% males compared with 58.0% 
females)
1
. Common disorders associated with ID such as Fragile X syndrome (FXS) and 
autism spectrum disorder (ASD) are more common in males than females
18,133
. Girls were 
excluded from both the test and control cohorts because: 1) testing girls using PCR for 
FMR2 mutations presents a problem in the female population as all females carry two X 
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chromosomes and therefore all alleles that are homozygous for FMR2 would have 
required additional testing by Southern blot to rule out a possible expansion; and 2) 
females with full FMR2 expansions have milder phenotypes than males with full FMR2 
expansions and were less likely to exist in the PMGP retrospective cohort because the 
likelihood of being referred for a clinical genetics assessment is relatively low.  
 
4.1.3 Control Cohort 
The controls for this study were previously recruited through random-digit-dialing 
as controls for a study on colorectal cancer. These individuals had agreed to allow their 
anonymized samples to be used in other research studies. This was an adult control group, 
the majority of whom were over the age of 40 (704/720 [97.8%])
120
. Ideally the control 
cohort would have been comprised of neurotypical boys between the ages of 2-19; 
however, such a cohort was not available. The controls tested were matched for gender 
and provided a representative sampling of the Newfoundland population. Although it is 
unknown whether any of the controls had ID, a history of developmental delay or a 
learning disability, the chance of this was reduced because each participant completed 
several detailed hand-written questionnaires.  
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4.1.4 Patient recruitment 
Recruitment in the study was lower than anticipated in both the family and 
retrospective cohorts. The research team did not attempt to enroll Family B as the family 
was not interested in a follow up appointment with PMGP.  
Family A had two boys with FMR2 expansions, but only one (IV-1 who had a 620 
FMR2 repeat expansion) was seen in clinic. The proband’s aunt (III-8, 87 repeat 
premutation), although willing to give permission for her DNA sample to be used, was 
not interested in a follow up appointment for herself or her son (IV-7) who carried a 287 
repeat expansion. It would have been beneficial to have an assessment on the proband’s 
affected cousin to compare how the disease presented itself within this family. The 
proband’s mother had no contact with her brother (III-10) so it is unknown if he or his 
daughter (IV-9) carried an FMR2 expansion. If his daughter (IV-9) carried a premutation 
or expansion and had a son, he would be at 50% risk of having FRAXE.  
 The proband for Family C (III-1 who had a 250 FMR2 repeat expansion) was 
living in a group home and had little contact with his biological mother and no contact 
with his biological father. Therefore, no additional family members (apart from his sister, 
III-2 who had a 750 repeat expansion) could be invited into the study.  
 In Family E, the 13 year old proband had a mosaic full mutation (~300, 420 
repeats). Although multiple generations were available for testing, the proband’s mother 
(III-2, 950 repeat expansion) chose not to have her two other children (IV-2, IV-3) tested 
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for an FMR2 allele size. Although the mother reported no issues in these children, they 
were not assessed clinically and the mother declined genetic testing.  
 The retrospective cohort had a participation rate of 58.2% (92/158). The 
participation rate for the Janeway cohort could not be calculated and will be discussed in 
detail in the limitations section of the discussion. In a review article summarizing 
participation level in genetic research, the authors reported a range anywhere from 21% to 
85% of individuals are willing to participate in genetic research
134
. In general, individuals 
have mixed views on participating in genetic research studies. A recent study looking at 
public attitudes about genetic research in NL found that although the majority of 
participants supported genetic research, there were several areas of concerns
135
. In 
particular, individuals worried about the storage and protection of genetic information, 
the potential misuse of genetic information to promote social discrimination and the issue 
of information to third party groups (in particular, insurance companies)
135
.  
 ID is a very sensitive topic for many families and may have contributed to the 
overall willingness of parents to participate. Families that have a child with an ID or 
developmental delay often have additional strains on their time due to numerous 
appointments (speech therapy, occupation therapy, physiotherapy, etc.) required for the 
health and well-being of their child and may feel they do not have the time to participate 
in research, particularly if they perceive that there will be no direct benefit to their family.  
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4.2 FMR2 Analysis 
 
4.2.1 PCR-based FMR2 Testing 
Overall, interrogating the FMR2 locus was problematic. Standard PCR conditions 
did not work for this locus. It is highly repetitive and has a high GC content. GC rich 
amplicons are more stable and therefore require a higher than normal melting 
temperature. In order to alleviate this, multiple experiments were performed under 
conditions favourable to GC rich amplicons such as higher annealing temperature, higher 
MgCl2 concentration and polymerase Taq kits specific for GC rich areas
136
. By using 7-
deaza-dGTP, in combination with DMSO and betaine, and a slightly longer initial 
denaturation time, successful amplification was achieved. 
All samples tested were in the normal range except for two samples (one from the 
retrospective cohort and one from the control cohort), which failed to produce a visible 
amplicon. Possible explanations for this included human error, insufficient DNA quality 
or lack of amplification of the product either due to a single nucleotide polymorphism 
(SNP) in the primer preventing binding or due to an expansion in the FMR2 repeat region. 
A new aliquot for each sample was obtained, but revealed the same result. Additional X 
chromosome markers were tested to ensure the DNA was of sufficient quality for 
amplification and each marker produced a result. 
 The samples were sent to an outside research laboratory for expansion testing and 
one sample in the retrospective cohort was found to carry an FMR2 expansion. It was not 
surprising that 1.1% (1/92) of boys were found to carry an FMR2 expansion as it was 
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postulated that the NL population may be enriched for FMR2 expansions. Comparing our 
findings to published reports, 77.8% (28/36) of studies were unsuccessful in finding an 
FMR2 expansion in their populations
29-32,39,46,47,100-104,106-111,123-131,137
. A very large study 
of 3,738 boys only identified one boy with an FMR2 expansion
34
. The at-risk cohorts that 
were tested in previous studies included children (both males and females) with ID and/or 
academic difficulty, individuals with ASD, OCD, Parkinson’s disease and POF 
(Appendix L – Supplementary Table S.1). In studies with comparable inclusion criteria 
to this study, individuals who were negative for FMR1 expansions and who had 
developmental delay and/or ID (n = 841), no FMR2 expansions were observed
102,109,124
.  
 The sample from the control cohort that failed to produce an amplicon was also 
sent to an outside research laboratory for expansion testing and was found to be in the 
normal range. As mentioned above a possible explanation for this result may be that there 
was a SNP in the primer region preventing binding. Since the initiation of this study, the 
number of known SNPs has grown exponentially. Cross referencing the primer sequence 
against known SNPs in SNPCheck3 and AluMut Visual®, no SNPs were found. This 
individual may have a rare SNP in the primer that has not been reported in the literature, 
perhaps unique to the Newfoundland population. As the primer used by the research 
laboratory may have been different than the primer used in this study, this may explain 
why the external laboratory was able to obtain an amplicon.  
 If a larger Janeway cohort had been assembled it may very well have identified 
additional boys with FMR2 expansions as this cohort more closely matched the FRAXE 
phenotype description. The Janeway cohort was made up of only 14 boys and information 
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on their eligibility criteria was not forwarded to the research team. The problems with 
recruitment and lack of tracking information are discussed in greater detail later in the 
discussion (section 4.5). Overall the number of boys enrolled in the Janeway cohort was 
too small to make any inferences regarding this population of children.  
  
4.2.2 Anomalies within the test results  
The genotyping for the FMR2 repeat looked unusual for a small number of 
samples in the at-risk populations (the retrospective and Janeway cohorts) as well as the 
controls. The samples appeared heterozygous; however, in each case the allele size was 
within one repeat size of the other (i.e., 15, 16). In the case of a true heterozygote allele, 
which differ by one repeat, the smaller allele will produce a larger peak than the higher 
allele because it has the combined effect of its allele size and the stutter of the higher 
allele. However, this was not the case in these samples. By rerunning the plate or 
repeating the PCR with less DNA for most of these samples, this phenomenon 
disappeared indicating that it was an artifact of the PCR amplification. The probable 
explanation for this observation is amplification slippage
138
. If a mistake occurred in the 
first couple of rounds of PCR amplification, then the true amplicon and the artifact 
amplicon would be amplified in similar proportions, showing a result that looked like a 
heterozygote. For the test samples, additional testing was performed by Southern blot to 
ensure that indeed this was a mistake during PCR replication and not a true heterozygote. 
The control samples (n = 8) that did not resolve after repeat PCR where excluded from 
the cohort. 
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A single control sample (C49) presented with a unique finding – two alleles for 
FMR2 were observed. It was speculated that human error when pipetting the sample into 
the test well was the explanation, as a male sample would only have one allele for an X 
chromosome marker. To address this possibility, a new sample was requested from the 
stock tube, which yielded the same result. To determine if this was something specific to 
the FMR2 gene, additional X chromosome markers were tested and the sample produced 
two alleles for markers DXS1226, and DXS1214, indicating the presence of two X 
chromosomes. It was possible the sample was female and a mix up had been made by the 
laboratory when the DNA was extracted for the CRC study or alternatively, that the 
patient had a sex chromosome aneuploidy. To determine if indeed the sample was male, 
three Y chromosome markers were tested and for each marker an amplicon was seen 
suggesting the karyotype for this individual was 47,XXY (Klinefelter syndrome). 
 Klinefelter syndrome is a chromosomal disorder that results when a male has an 
extra copy of the X chromosome. It often goes undiagnosed until adulthood. An affected 
male may be identified when he fails to go through normal puberty or when he is unable 
to have children. The phenotypic features include small testicles, enlarged breasts, sparse 
facial and body hair with the inability (or reduced inability) to produce sperm. It is the 
most commonly observed sex chromosome anomaly and occurs in 1 in 500 – 1 in 1000 
males
139
. In this particular case, the sample was an anonymized one from the CRC control 
group and therefore this type of phenotypic information was not available.  
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4.2.3 Repeat Range in the Newfoundland Population  
The most common allele size seen in both the retrospective cohort and the NL 
controls was 12 CCG repeats and no sample carried an intermediate or premutation allele 
for FMR2. In the literature, the most common allele size identified was 15, although 
depending on the population mean normal allele sizes of 13, 14, 16 and 17.59 were also 
seen 
29,30,46,89,100-105,107-110
. The retrospective study had two allele sizes (3 and 6) not seen 
in the controls. To determine if there was a difference in minimal allele size (>10) in the 
test population versus the controls, a Fisher test was performed showing no significant 
difference between the two population groups (p = 0.81).  
 It was expected that the Newfoundland population would carry alleles in the 
higher range as this might be a possible explanation as to why there are more cases 
reported here than anywhere else in the world. However, this was not the case. In fact, the 
NL population exhibited a smaller modal size than other reported populations.  
 As mentioned in the results (section 3.2.1.1), the repeat size obtained using 
fragment analysis differed by three repeat sizes from the result obtained by Sanger 
sequencing. This is a common anomaly noted in other studies looking at trinucleotide 
repeats
140
. In order for this study to be compared with the repeat sizes reported in the 
literature, the repeat size was not corrected for by the sequencing factor. Of all the studies 
that reported on repeat size only a small number of publications reported they adjusted by 
sequencing result. This is an important factor to consider when making inferences 
between different research studies. However, if the repeat size in the NL population was 
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adjusted for by the sequencing factor, then the most common repeat size is 15 CCG 
repeats.  
 Although a common practice in the literature, it is very difficult to compare repeat 
sizes across different published reports. Repeat sizes can differ between laboratories 
based on a number of factors including: the primers used, which primer was labelled 
(forward or reverse), binning criteria, and differences in equipment, chemistry and the 
fluorophore used. The actual repeat size for an individual is not critical, only which repeat 
class they fall into – normal, intermediate, premutation or full mutation. For any result 
that falls near the borderline of two repeat classes, a second method for investigating 
repeat size should be used.  
 
4.3 Clinical description of FRAXE positive families 
 
Due to the suspected excess of FRAXE cases in Newfoundland, we hoped to 
refine the FRAXE phenotype that has been reported in the literature. Reviewing the 
positive cases in this province largely confirmed what is in the literature with regards to 
the phenotype. All four probands (Families A, C, D and E) had learning problems, three 
had delayed speech (Families A, C and D), three had attention difficulties (Families C, D 
and E) and two were formally diagnosed with ADD (Families D and E). These are all 
known features of FRAXE.  
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For three of the four probands where formal IQ testing was available, one had 
mild ID (Family A, FSIQ 54), one had a borderline low IQ (Family C, FSIQ 71) and one 
had an IQ within the normal range (Family E, FSIQ 96) with a formal diagnosis of ADD. 
The fourth proband (Family D) had delayed early childhood milestones, and at age 10 
years followed an alternative curriculum at school and so very likely had at least a 
borderline-low IQ, if not mild ID. We suggest that it is important point for clinicians to 
consider the possibility of an FMR2 expansion in a boy with an IQ in the normal range 
who has other neurobehavioral abnormalities (e.g. learning disability, ADD/ADHD), 
particularly if that boy comes from NL.  
 Unlike the other children with positive FMR2 expansions, the Family A proband 
had a more severe phenotype. He was the only child referred to the PMGP due to 
developmental delay and a syndromic appearance. He had facial features similar to those 
observed in FXS and had mild ID by formal psychometric testing.  
 A comparative genomic hybridization (CGH) microarray was ordered to rule out 
any additional genetic contributors to his phenotype and the patient carried a small 
deletion of 1p36.33 (less than 1 Mb). This proband’s deletion overlaps a much larger 2.5 
Mb that is associated with a contiguous gene deletion syndrome, monosomy 1p36 
syndrome. For this syndrome, the size of the deletion influences the phenotypic 
features
141
. The prevalence of this syndrome is estimated to be 1 in 5,000 to 1 in 10,000 
births, with a 2:1 female to male ratio and all affected individuals have developmental 
delay or ID
142
. 1p36 deletion syndrome has typical dysmorphic features that include 
microbrachycephaly, midface retrusion, straight eyebrows, deep set eyes, epicanthal 
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folds, wide and depressed nasal bridge, long philtrum, pointed chin, large anterior 
fontanel and low-set ears
142
.  
 The Family A proband was very dysmorphic, but his appearance was not 
consistent with 1p36 deletion syndrome. Instead of having a small head circumference 
(microcephaly), he had macrocephalic with very different facial features that included a 
prominent forehead and jaw, a long narrow face, hypertelorism (widely spaced eyes), 
large ears, high arched palate, thick lips and teeth irregularities. For the Family A 
proband, it is unlikely that his heterozygous 1p36.22 deletion explains the severity of his 
phenotype, including his highly dysmorphic appearance, as it is also present in his father 
who does not have ID and who is not dysmorphic. 
The Family A proband had a very syndromic appearance, and the Family C and D 
probands were mildly dysmorphic, which is in contrast to the fact that FRAXE is 
classified as a non-syndromic form of ID. Again, this is an important consideration for 
clinicians, particularly in NL. Since the conclusion of the study, whole exome sequencing 
(WES) has been introduced into diagnostic laboratories and is recommended as an early 
investigation for dysmorphic children with either ID or an autism spectrum disorder 
(ASD)
143. This technology allows scanning of most of the genome’s 22,000 exons for 
mutations, but fails to pick up triplet repeat disorders. FRAXE syndrome should be 
included in the differential diagnosis list for a syndromic appearing boy with ID or other 
neurobehavioral abnormalities, particularly if the child comes from NL, as FMR2 
expansions are often not detected by WES. 
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The fact that three out of the four FRAXE families were ascertained by the PMGP 
for indications other than ID in the proband suggested that FRAXE may very well be 
under diagnosed in the NL population. Only one of the probands (IV-1 of Family A, 620 
FMR2 expansion repeat) was referred to genetics because of ID. This proband had more 
severe delay than the other five affected boys and was very dysmorphic. Two of the other 
probands were originally referred to the PMGP due to known genetic conditions in other 
members of their family. The Family C proband (250 FMR2 repeat expansion) was 
referred because his biological mother had neurofibromatosis type 1 (NF1). When he was 
assessed, there were no features of NF1 on physical examination, but learning difficulties 
in school were noted. FMR2 was not standard testing at the time and only FMR1 testing 
was arranged. The proband for Family D was seen for a family history of multiple 
endocrine neoplasia type 1 (MEN-1), of which he was negative. He tested negative for the 
family mutation, but the genetic counsellor identified that he had academic difficulties, 
and FMR1 and FMR2 testing were ordered. The Family E proband had learning 
difficulties and a diagnosis of ADD but was not referred for genetic assessment because 
of either of these. A consultation was requested because his aunt was found to have an 
Xq27 cytogenetic fragile site as part of a work up for infertility that was due to a large 
FMR2 expansion (400-700 repeats).  
 Another interesting finding was that in two out of the four families, fertility issues 
were documented. In Family A, an aunt of the proband (III-6) was infertile and she 
carried an approximately 80-100 unmethylated FMR2 expansion. In turn, by history two 
of her aunts (II-4, II-5) were unable to conceive children (their DNA was not tested as 
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part of this study). In Family E, the FMR2 expansion was identified through chromosome 
analysis testing of the aunt (III-5) who was undergoing in vitro fertilization (IVF) 
treatment as described above.  
 Primary ovarian failure (POF) is defined as the cessation of menses for 6 months 
before the age of 40
39
 and is well documented in FXS. Women who carry premutations in 
the FMR1 gene have a 12.9 to 21.0% chance of having POF
42,43
. Contrary to FMR1, the 
relationship between FMR2 and POF is not well understood. There have been no 
published reports that have documented women with premutations in FMR2 who also had 
had POF. One study by Murray reported six women with POF that had minimal (<11 
repeats) alleles for FMR2, three of whom had microdeletions within the gene
47
. This was 
a follow up study from a previous paper investigating minimal alleles in individuals with 
POF versus controls in which the authors found a significant difference between the two 
groups
39
.  
 Our study suggests that the association between POF and FMR2 allele size should 
be further investigated. We identified two women with unexplained infertility who carried 
FMR2 expansions: In Family A, a maternal aunt of the proband (III-6), who had a 
premutation allele of approximately 80-100 repeats and in Family E, a maternal aunt of 
the proband (III-5) who had mosaicism for a full expansion of 400-700 repeats. 
 
4.4 Founder effect 
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4.4.1 Newfoundland population and founder effect  
The province of Newfoundland and Labrador is constructed from a small number 
of founders and is composed of genetic isolates
113
. As described in more detail in the 
introduction, this province has a young history with first colonization occurring in the 17
th
 
century from only 20,000 settlers. Communities were established along the coast, and 
travel between communities was restricted due to geography and ruggedness of the area. 
Religious segregation combined with little emigration resulted in unique genetic 
populations. 
 In this study, we report four families that have FMR2 expansions. One additional 
family is known to the PMGP to have FRAXE but was lost to follow up. The rarity of the 
disease, coupled with the genetic structure and history of the province, suggests that these 
families may have a common founder or ancestor. To test this theory, the Newfoundland 
Genealogy Database (NGD) was utilized to determine if indeed these individuals shared a 
common ancestor.  
 
4.4.2 Newfoundland Genealogy Database  
It was surprising that a common ancestor could not be identified between these 
families. The Newfoundland Genealogy Database (NGD) is a unique resource 
constructed using census records from 1911, 1921, 1935 and 1945. It was complemented 
by Stonepics, a collection of pictures of headstones throughout the province, historic 
church records of births and marriages throughout the province from various 
denominations, as well as numerous online resources containing genealogy information 
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on families in Newfoundland. Using the NGD, making connections to Family C and E 
was difficult. The proband in Family C was living in foster care at the time of the study 
and his biological parents were unavailable to clarify any pedigree questions. The 
proband’s father was born after 1945 and therefore is too young for the NGD. The 
paternal grandparents are unknown to the proband. The proband’s maternal grandmother 
was placed in foster care at a young age and could not provide any genealogical 
information. For Family E, DNA was available for four generations of individuals, and 
therefore, it was possible to determine the side of the family that was segregating the 
expanded FMR2 allele. The proband’s great-grandmother (I-2) on the maternal side who 
carried a premutation, could not be found in the NGD and therefore the pedigree could 
not be extended. However, Family E did not share the same haplotype as the other 
families, therefore a common ancestor would not be expected.  
 Although the NGD is a valuable resource there are some limitations to its abilities. 
Firstly, it is comprised of census data of which there are missing records. The census 
records at the time were not held in a centralized location and some data was stored in 
individual’s attics and basements. Water damage and fire has destroyed some of the 
records. The census data was ascertained by individuals hired to go door-to-door to 
collect the information, therefore, there were undoubtedly mistakes made in transcription. 
If a household was not occupied at the time of the survey, the family’s data would not 
have been collected. Secondly, none of the information gathered during the census was 
verified by another source. It was not uncommon at that time for non-paternity issues to 
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be present in families. Although the NGD could not confirm a common ancestor between 
Family A, C and D, it did allow for considerable expansion to the pedigrees. 
 
4.4.3 Haplotype Analysis 
Although the NGD did not identify a common ancestor, using haplotype analysis 
seven markers were found to segregate in three (Family A, C, and D) out of the four 
families proving a common haplotype of at least 1.88 Mb was identified. Eight 
individuals from three separate families shared this haplotype. In Family A, the haplotype 
was present in the proband (IV-1), his mother (III-2) and his two aunts (III6, III-8); all 
three of these women carry premutations. For Family C, no parental DNA was available 
but the haplotype was present in the proband and his sister (III-2) who carried a full 
FMR2 expansion. Three generations of Family D were tested and both the proband (III-1) 
and his premutation mother (II-2) carried the shared haplotype. The maternal 
grandmother (I-2) who had two normal FMR2 alleles had a different haplotype.  
Family E did not share the common haplotype seen in Family A, C and D. This 
family had 4 generations available for testing and the proband (IV-1), his premutation 
mother (III-2), his premutation grandmother (II-2), and his premutation great-
grandmother (I-2) all carried the same haplotype which was different from the haplotype 
observed in the other 3 families.  
A control sample was also haplotyped to compare with the families and this 
sample did not share either of the disease haplotypes observed in Families A, C and D or 
Family E.  
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It was postulated that the four families investigated would have the same 
haplotype suggesting the possibility of a founder effect; however, this was not the case. It 
was surprising in a population of approximately 500,000 people that two different 
haplotypes were observed. This supports the theory that FRAXE is more common here 
than other populations previously investigated. 
 
4.5 Limitations 
This study had several limitations. The purpose of the Janeway cohort was to 
increase the possibility of identifying additional FRAXE cases in the NL population in a 
cohort of boys with milder phenotypes than those that would typically lead to a clinical 
genetics referral. However, recruitment for this part of the study was poor and for the 14 
individuals who were recruited, little phenotypic information was received; therefore, 
they were excluded from the comparison of the FMR2 repeat size in the at-risk test group 
versus the NL controls.  
The tracking form provided to the pediatricians could have provided information 
regarding recruitment however, it was never completed. By completing the tracking form 
the number of boys being seen in the clinic and their eligibility status would have been 
known. Because these forms were not received, it was not possible to determine if parents 
were provided information about the study, if parents declined the study and/or if parents 
were given the study package but did not follow up. Despite continued efforts to improve 
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recruitment, only 17 individuals were known to the research team, and a signed consent 
form was obtained from 14 parents.  
It is unfortunate that the recruitment issue could not be rectified and it was likely 
related to the fact that the clinic development clinic is a very busy environment. Currently 
on average 58 new patients and 441 follow up patients are seen per month in the 
Janeway’s Child Development clinic. Based on the number of patients and the 
assumption that only half of those would be eligible boys, with a participation rate 
comparable to the retrospective cohort (58.2%), 200 boys would have been anticipated.  
 As discussed above, although people accept the idea of genetic research, many 
individuals do not wish to participate. Parents of children with special needs may be 
particularly sensitive to participating in such research studies when there is no perceived 
direct benefit to their child. Although it is difficult to determine why recruitment was so 
poor the stipulation of having a blood drawn may have contributed. Many children at 
Child Development are seen by their pediatrician on a regular basis, but would not 
necessarily have bloodwork done at each appointment. As having a blood draw can be 
traumatic for many children, especially those with ID, this may have excluded a large 
number of potential participants. The busy workload of the physicians may also have 
contributed to the lack of recruitment as they may have been too busy to explain the 
study. In hindsight, hiring a research nurse would have helped the recruitment phase of 
this study. The research nurse could have provided information to all parents who were 
interested in the study and answered any questions, allowing parents to decide if they 
wished to participate before a blood sample was drawn. The research nurse could also 
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have completed the tracking form to provide information of eligible criteria and capture 
the number of individuals who were eligible, but not interested in participating. 
Unfortunately, the pediatricians each have different clinic days throughout the week and 
funds were not available for a research nurse for this study. 
 With regards to the families, ascertainment was also a limitation. As discussed in 
section 4.1.4, many families had key individuals who were unavailable or not willing to 
participate in the research study. In Family A, updated clinical assessment for the 
proband’s cousin (IV-7) who also carried a full expansion could have provided more 
information about the FRAXE phenotype in the Newfoundland population. Although the 
mother reported some academic difficulty in her son, he was working away from home 
and therefore had a much milder phenotype than the proband, who had mild ID. It would 
have been helpful to have IQ assessments for the two brothers, IV-2 and IV-3, who did 
not carry FMR2 expansions to compare the baseline for intellectual ability within the 
nuclear family. The proband’s mother (II-2) in Family C was unavailable for testing and 
the proband had no contact with his father (II-1), therefore it could not be determined 
which side of the family, the maternal or paternal, passed on the expansion to their 
children. The proband in Family E also had two siblings with unknown FMR2 status. This 
proband had IQ testing which was in the normal range. It would have been valuable to 
compare his IQ testing results with that of his siblings, if negative, to see if the FMR2 
expansion was having an effect on his intellectual ability. If this was the case, one would 
expect the siblings IQ results to be higher (high normal range) than that of their brother. 
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As well, there have been reports in the literature of siblings with FMR2 expansions, who 
have normal phenotypes
83
.  
 Another limitation of this study was that only males were included. Although the 
reasoning for this decision was sound, based on the number of premutation females in our 
families (n = 7) there may be an excess of premutation carriers in the population. In 
Family E there are two full mutation females and although could not be formally 
assessed, they had no apparent phenotype. It is possible that additional full mutations 
females are present in the NL population who either have no manifestations or who are so 
mildly affected that they do not come to medical attention.  
 
4.6 Summary and Conclusions 
We conclude that the minimum prevalence of FRAXE syndrome in the NL 
population is 6 out of 46,420 or 1 in 7,737 in the male pediatric population which is 6-
fold the prevalence seen in the general population.  
Our data supports the hypothesis that the NL population is enriched for FMR2 
expansions. Firstly, in our retrospective of 92 boys with negative FMR1 testing, we 
identified one boy with a full FMR2 expansion. Secondly, for three out of the four 
families ascertained through referral to the provincial genetic service, the FMR2 
expanded allele occurred on a shared 1.88 Mb haplotype, consistent with a founder effect. 
For the four FRAXE male probands identified because of referral for a clinical 
genetic assessment, only one was referred for ID. Two other probands were referred 
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because of a family history of an unrelated genetic disorder and the fourth was referred 
because of a cytogenetic fragile site in a maternal aunt. This observation is consistent 
with our hypothesis that FRAXE expansions are under ascertained in the NL population. 
The study confirms that the phenotype in males with full FMR2 expansions 
includes ID, but that not all such males have an IQ that is outside the normal range. All 
four males in whom we identified full FMR2 mutations had learning problems, three had 
delayed speech and three had attentional problems; these neurobehavioral abnormalities 
have all previously been associated with the syndrome.  
Although FRAXE syndrome is classified as a non-syndromic form of ID, one NL 
male proband was strikingly dysmorphic, with features highly reminiscent of the physical 
features seen in some males with full FMR1 mutations. Another two males with full 
FMR2 expansions were mildly dysmorphic. We therefore suggest that FRAXE syndrome 
be included by clinicians in the differential diagnosis list for a syndromic appearing boy 
with ID or other neurobehavioral abnormalities, particularly if the child comes from NL. 
 Currently when such children are assessed by a clinical geneticist and a syndrome 
cannot be diagnosed based on clinical features, the first line test is a genome-wide 
microarray. If the array is normal, Canadian guidelines suggest that the child have whole 
exome sequencing (WES) and this test will not identify triplet repeat expansion disorders 
like Fragile X and FRAXE syndromes. 
We suggest FMR2 genetic testing in any NL male (with or without dysmorphism) 
who has unexplained ID. Our study showed that FMR2 expansions also exist in NL boys 
with milder neurobehavioral abnormalities that include learning disabilities and 
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ADHD/ADD. Consideration should be given to testing this population of NL males, 
particularly if there is a strong family history of academic difficulties or attentional 
problems or if that male is seeking preconceptional genetic counselling. 
 Regarding FMR2 testing of females in this population, we make the following 
observations. Firstly, in the four Newfoundland families ascertained through the PMGP, 
there were three females segregating full mutations: (1) the sister of proband C who had 
academic difficulty requiring modifications within the school system and (2) the mother 
and (3) the maternal aunt of proband E both of whom have post-secondary education. 
Secondly, we identified two women with unexplained infertility who carried FMR2 
expansions: In Family A, a maternal aunt of the proband who had a premutation allele of 
approximately 80-100 repeats and in Family E, a maternal aunt of the proband who had 
mosaicism for a full expansion of ~ 400-700 repeats. 
There is a known association between POF and FMR1 premutations, and our 
study suggests that the association between POF and FMR2 allele size should be further 
investigated, particularly in this population. 
The indications for FMR2 genetic testing in NL females are less clear than for 
males, but we suggest considering the test in girls with a personal and family history of 
developmental delay and/or ID and in women with POF who have had negative FMR1 
genetic testing. 
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Hello, could I speak to ____________________. 
 If not available: Thank you. I will call again later. Could you suggest a time that might be 
better? 
Hello ____________________, My name is __________________. I am a research student at 
Memorial University working with Dr. Fernandez. As you may recall Dr. Fernandez tested your 
son for Fragile X. We are interested in doing a research study about children who tested 
negative for Fragile X. I would like to tell you more about this study. Is now a good time to talk? 
 If no: Could you suggest a better time? 
As you know your child tested negative for a FRAXA mutation. We now know about another 
gene that may cause developmental delay and would like to test your child for it. The gene is 
called FRAXE. This is a very rare form of Fragile X syndrome. We have recently found several 
children in Newfoundland with FRAXE. We suspect that FRAXE may be more common in 
Newfoundland than in other places. If this new mutation is the cause of your child’s 
developmental delay, we ask you to come back to the genetics clinic so that we can fully explain 
the test result.  
Your participation in this study is completely voluntary and you are under no obligation to take 
part. If you do agree to join the study, you can withdraw at any time. 
Are you interested in the study? 
 If no: Thank you for your time. Goodbye. 
I will send you a consent form. It explains the study in more detail and explains your rights and 
who you can contact for more information. You will have to sign the consent form in order to be 
in the study. I will send it out to you in the next few days and I will call you in 10 days to see if 
you received it. At that time we can go through the consent form and answer any questions or 
concerns you may have about the study. When we have received your signed consent, we will 
proceed with the study. 
Do you have any questions? 
Thank you for your time and I will be talking to you soon. 
Goodbye.  
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October 2003 
Faculty of Medicine, Schools of Nursing and Pharmacy of Memorial 
University of Newfoundland; Health Care Corporation, St. John’s; Newfoundland 
Cancer Treatment and Research Foundation 
 
Consent to Take Part in Health Research 
 
TITLE: Is FRAXE syndrome over-represented among Newfoundland children with 
cognitive impairment?  
 
INVESTIGATOR(S): Ms. Amanda Dohey, Dr. Ban Younghusband, Dr. Bridget Fernandez, 
Ms. Marian Crowley  
 
SPONSOR:  
You have been invited to take part in a research study. It is up to you to decide whether 
to be in the study or not. Before you decide, you need to understand what the study is 
for, what risks you might take and what benefits you might receive. This consent form 
explains the study.  
 
The researchers will:  
 discuss the study with you  
 answer your questions  
 keep confidential any information which could identify you personally  
 be available during the study to deal with problems and answer questions  
 
If you decide not to take part or to leave the study this will not affect your usual health 
care.  
 
1. Introduction/Background:  
In most populations Fragile X (type A) is the most common form of inherited developmental 
delay. However in Newfoundland there has only been one individual known to have Fragile 
X (type A). There is new information that suggests another gene may be responsible for mild 
to moderate developmental delay in our population. In this study we would like to test all 
children who had negative FRAXA for an alteration in another gene called FRAXE. This will 
help us not only to determine the number of individuals with FRAXE but also to learn more 
about individuals who have it.  
 
2. Purpose of study:  
- to determine if children with unknown developmental delay have FRAXE mutations  
- to describe the characteristics of people with FRAXE  
 
3. Description of the study procedures and tests:  
If you decide to take part in this study, your child’s banked DNA will be tested for FRAXE. 
You will be informed of the result of this testing. If the test is positive, you will be asked to 
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attend a clinic appointment with Dr. Fernandez and Ms. Dohey. Here the result will be 
explained in more detail. Dr. Fernandez will also re-examine your child at this time. You will 
receive genetic counselling and the option of genetic testing for other family members will be 
discussed.  
 
4. Length of time:  
For patients who test positive, a visit to the genetics clinic will be requested. The visit will 
last approximately 1 hour.  
 
5. Possible risks and discomforts:  
There are no risks associated with this study. New referrals will have the discomfort of 
providing a blood sample.  
 
6. Benefits:  
It is not known whether this study will benefit you. However it may allow your child to 
have an additional form of genetic testing which may lead to the identification of the 
cause of your child’s developmental delay.  
 
7. Liability statement:  
Signing this form gives us your consent to be in this study. It tells us that you 
understand the information about the research study. When you sign this form, you do 
not give up your legal rights. Researchers or agencies involved in this research study 
still have their legal and professional responsibilities.  
 
8. Confidentiality:  
Investigators will strive to maintain your privacy and keep your identity confidential. All 
computer files containing confidential information will be protected with password only 
access and all paper files will be kept in a locked filing cabinet.  
 
9. Questions:  
If you have any questions about taking part in this study, you can meet with the 
investigator who is in charge of the study at this institution. That person is:  
 
Amanda Dohey and Phone Number 777-XXXX 
 
Or you can talk to someone who is not involved with the study at all, but can advise you 
on your rights as a participant in a research study. This person can be reached through:  
 
Office of the Human Investigation Committee (HIC) at 709-777-6974 
Email: hic@mun.ca 
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Signature Page 
 
Study title: Is FRAXE over-represented among Newfoundland children with cognitive impairment?  
 
Name of principal investigator: Amanda Dohey  
 
To be filled out and signed by the participant:  
Please check as appropriate:  
I have read the consent [and information sheet].      Yes { } No { }  
I have had the opportunity to ask questions/to discuss this study.    Yes { } No { }  
I have received satisfactory answers to all of my questions.     Yes { } No { }  
I have received enough information about the study.     Yes { } No { }  
I have spoken to Ms. Dohey and she has answered my questions    Yes { } No { }  
I understand that I am free to withdraw from the study     Yes { } No { }  
 at any time  
 without having to give a reason  
 without affecting my future care [student status, etc.]  
 
I understand that it is my choice to be in the study and that I may not benefit.  Yes { } No { }  
 
I agree that the study doctor or investigator may read the parts of my hospital  Yes { } No { }  
records which are relevant to the study.  
  
I agree to take part in this study.        Yes { } No { }  
 
____________________________________ __________________________  
Signature of participant     Date  
 
____________________________________ _________________________  
Signature of witness     Date  
 
To be signed by the investigator:  
 
I have explained this study to the best of my ability. I invited questions and gave answers. I believe 
that the participant fully understands what is involved in being in the study, any potential risks of the 
study and that he or she has freely chosen to be in the study.  
 
____________________________________ __________________________  
Signature of investigator     Date  
 
Telephone number: _________________________  
 
Assent of minor participant (if appropriate):  
 
____________________________________ __________________________  
Signature of minor participant    Date  
 
____________________________________ __________________________  
Relationship to participant named above   Age  
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Signature Page 
 
Study title: Is FRAXE over-represented among Newfoundland children with cognitive impairment?  
 
Name of principal investigator: Amanda Dohey  
 
To be filled out and signed by the participant:  
Please check as appropriate:  
I have read the consent [and information sheet].      Yes { } No { }  
I have had the opportunity to ask questions/to discuss this study.    Yes { } No { }  
I have received satisfactory answers to all of my questions.     Yes { } No { }  
I have received enough information about the study.     Yes { } No { }  
I have spoken to Ms. Dohey and she has answered my questions    Yes { } No { }  
I understand that I am free to withdraw from the study     Yes { } No { }  
 at any time  
 without having to give a reason  
 without affecting my future care [student status, etc.]  
 
I understand that it is my choice to be in the study and that I may not benefit.  Yes { } No { }  
 
I agree that the study doctor or investigator may read the parts of my hospital  Yes { } No { }  
records which are relevant to the study.  
  
I agree to take part in this study.        Yes { } No { }  
 
____________________________________ __________________________  
Signature of participant     Date  
 
____________________________________ _________________________  
Signature of witness     Date  
 
To be signed by the investigator:  
 
I have explained this study to the best of my ability. I invited questions and gave answers. I believe 
that the participant fully understands what is involved in being in the study, any potential risks of the 
study and that he or she has freely chosen to be in the study.  
 
____________________________________ __________________________  
Signature of investigator     Date  
 
Telephone number: _________________________  
 
Assent of minor participant (if appropriate):  
 
____________________________________ __________________________  
Signature of minor participant    Date  
 
____________________________________ __________________________  
Relationship to participant named above   Age  
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<Insert Date> 
 
Dear Parent(s): 
 
I hope you had a relaxing summer with your family. As you may recall earlier this year we spoke 
about enrolling your child in the FRAXE study. For your convenience I have enclosed another 
copy of the consent form in case it has been misplaced over the summer break. It would be 
much appreciated if you could you please send in your form indicating whether or not you are 
interested in this study. 
As per our conservation, testing is occurring now and in order for your child to participate, this 
consent form must be returned by <insert date>. If I do not receive the signed consent form by 
<insert date> I will assume that you are no longer interested in participating in this study and I 
will not contact you further. 
If you have any questions regarding this study or the consent form, please do not hesitate to 
give me a call at 777-XXXX. 
 
Sincerely, 
 
Amanda Dohey 
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Child’s Name:_______________________________________ 
MCP #: ____________________________________________ 
Parents Name: _______________________________________ 
Parents Signature: ____________________________________ 
 
 Future use of tissue/DNA samples: 
In order to preserve a valuable resource, your child’s DNA samples may be stored at the end 
of this research project. It is possible that these samples may be used in a future research 
project. This project will be related to childhood diseases as determined by a research ethics 
committee. Any future research would have to be approved by a Research Ethics Board 
(REB). 
Please tick one of the following options: 
 I agree that my child’s DNA sample can be used for approved childhood 
diseases research project without contacting me again, but only if my child’s 
name* cannot be linked, in any way, to the sample. 
 Under no circumstances may my child’s sample be used for future research. 
My child’s sample must be destroyed at the end of this present project. 
 I agree that I may be contacted in future to be invited to provide consent for 
the use of my child’s DNA in any new approved research project.  
 
*Includes name, MCP number or any other identifying information. 
The DNA sample from this study will be stored in Dr. Woods lab, in the Discipline of 
Genetics at the Health Sciences Centre, St. John’s, Newfoundland for an indefinite 
period of time. 
 
 
You may withdraw your child’s sample at any time without affecting your child’s future care 
by contacting Ms. Amanda Dohey at 777-XXXX or Dr. Bridge Fernandez at 777-XXXX at which 
time we will destroy your child’s DNA sample. 
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FRAXE Project 
Faculty of Medicine 
Health Sciences Centre 
 
Dear Parent: 
Enclosed is a special consent form that tells us what to do with your child’s DNA sample after the 
study is over. Please take the time to read this special consent form, choose the option that best 
suits your family and return in the envelope provided.  
DNA is a valuable resource and if you choose to participate in a future genetic study this sample 
could be used with your permission without having to draw an additional blood sample from 
your child. 
However if I do not receive your response by November 1, 2009 I will assume that you would like 
your child’s DNA destroyed and the sample will be disposed of.  
Once again I would like to thank you and your son for your participate. If you have any further 
questions regarding this form or the study in general please do not hesitate to call me. 
 
Sincerely, 
 
Amanda Dohey 
FRAXE Research Co-coordinator 
Amanda Dohey 
Younghusband Research Lab 
Discipline of Genetics, Room 4333 
Health Sciences Centre 
300 Prince Philip Drive 
St. John’s, NL  A1B 3V6 
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FRAXE STUDY 
 
Is FRAXE over-represented among Newfoundland children with cognitive impairment? 
Investigators:  Ms. Amanda Dohey 
     Dr. Bridget Fernandez 
     Dr. Ban Younghuband 
            Ms. Marian Crowley 
Inclusion Criteria 
Nonsyndromic boys between the ages of 3-18 with the following criteria: 
1. two of the four criteria 
1) Speech delay requiring speech therapy; 
2) Learning disabilities or academic difficulties requiring alternate school 
programming at school (could be as mild as “pathway 2” school); 
3) Behavior abnormalities necessitating input from a behavior management or 
child management specialist (including a diagnosis of attention deficit disorder, 
aggressive behaviors); 
4) IQ testing that shows borderline (IQ = 70-80) or mild (IQ = 50-70) MR  
and 
2. will not be referred to Medical Genetics and  
 
3. having blood drawn and  
 
4. no known etiology. 
 
 
 
Contact Information: Amanda Dohey 
   Room # - H4333 
   Email address - acareen@mun.ca 
   Phone # - 777-XXXX 
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Appendix H – Tracking form for Janeway cohort 
 
  
171 
 
 
 
 
 
Dr: ___________________________________  
 FRAXE STUDY 
 Amanda Dohey - Investigator (777-6989) 
 
 
 
 
Patients Name 
 
Two of the four criteria 
 
 
Not Referred 
to Genetics 
 
 
Having Blood 
Drawn 
 
 
No Known 
Etiology 
 
 
Eligible 
 
 
Package 
 
Speech 
 
Learning 
 
Behavior 
 
IQ (<80) 
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Dear Parent, 
My name is Amanda Dohey and I am a masters student at Memorial University. I work with Dr. Bridget 
Fernandez, Geneticist at the Medical Genetics Department and Dr. Ban Younghusband, Head of the 
Discipline of Genetics at the Faculty of Medicine.  
Thank you so much for your interest in this study. This study looks at a gene called FRAXE which is found on 
the X chromosome. Defects or mutations in this gene have been found to be associated with various 
learning problems in children. It is through willingness of people like your family that we may eventually 
learn more about FRAXE and learning problems in general.  
I will be contacting you shortly to talk to you more about this study. Rest assured that your child’s sample 
will not be used until I have spoken with you and I have received the signed consent form. If you have any 
questions before that, you can call me at 777-XXXX. Thank you for taking the time to read this letter and I 
look forward to talking to you soon. 
 
Sincerely, 
 
Amanda Dohey 
Masters Student 
Memorial University of Newfoundland 
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FRAXE Project 
Faculty of Medicine 
Health Sciences Centre 
FRAXE Mutation Screening Report 
<Insert Date> 
Patient Name: 
DOB: 
MCP: 
DNA #: 
 
Molecular analysis indicates that (Child’s name) does not have an expansion at the FRAXE locus. 
Patient Name Date Obtained FMR-2 (CCG)n repeats Expansion Range 
    
 
Disease Background: FRAXE is a rare form of the Fragile X syndrome. Individuals with FRAXE tend to be slow 
learners, be hyperactive and exhibit language delay. The FRAXE gene is located on the X 
chromosome. The normal gene contains a three base pair sequence (CCG repeat) which 
varies in the general population. The normal range of CCG repeats is 6-30 repeats, whereas 
individuals affected with the disease have expansion ranges greater than 200 repeats.  
Analysis: (Child’s name) was tested using PCR analysis for the expansion of the FRAXE gene. 
Disclaimer: The testing for FRAXE expansions was performed in a research laboratory, not a licensed 
medical laboratory. Therefore the accuracy and quality of the results may not be as reliable as 
those from a licensed service lab. 
 
Amanda Dohey 
Research Co-coordinator for the FRAXE Project  
Amanda Dohey 
Younghusband Research Lab 
Discipline of Genetics, Room 4333 
Health Sciences Centre 
300 Prince Philip Drive 
St. John’s, NL  A1B 3V6 
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Appendix K – Mutation letter 
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FRAXE Project 
Faculty of Medicine 
Health Sciences Centre 
 
 
Dear ________________,  
 
Enclosed is your mutation report from the FRAXE study. As we previously discussed FRAXE is a rare form of the Fragile 
X syndrome. In this study we looked at defects or mutations in the FRAXE gene. In your child, the FRAXE gene was 
found to be in the normal range. Therefore your child’s medical problems are not the result of a FRAXE mutation. 
 
I would like to thank you for your participation in this study. It is through willingness of people like you that we may 
eventually learn more about FRAXE and learning problems in general.  
 
A copy of this mutation report has also been forwarded to Dr. Bridget Fernandez, Director of the Provincial Medical 
Genetics Program. If you have any questions regarding this result please do not hesitate to give me a call at (709)777-
XXXX. 
 
 
Once again thank you for your participate. 
 
Sincerely, 
 
 
Amanda Dohey 
FRAXE Research Co-coordinator 
 
  
Amanda Dohey 
Younghusband Research Lab 
Discipline of Genetics, Room 4333 
Health Sciences Centre 
300 Prince Philip Drive 
St. John’s, NL  A1B 3V6 
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Table S.1 – Summary of 36 studies evaluating FMR2 status 
 
Ref Population 
# of 
Individuals 
N
o
rm
a
l 
In
te
rm
ed
ia
te
 
P
re
m
u
ta
ti
o
n
 
F
u
ll
 M
u
ta
ti
o
n
 
Cohort Criteria Origin 
109 
At risk 300 300 0 0 0 
males negative for FMR1 
expansions 
Canada 
Control 28 28 0 0 0 healthy normal controls  
131 At risk 57 57 0 0 0 
families with ≥ 2 children 
with autism, PDD or 
Aspergers 
Canada 
102 At risk 397 397 0 0 0 
males and females living in 
an institution with 
developmental delay and 
negative for FMR1 
expansions 
 
129 At risk 737 737 0 0 0 
males and females with ID 
or 1st degree relative with 
ID 
Germany 
79 At risk 911 908   1+3 
negative for FMR1 
expansions 
United Kingdom 
100 At risk 462 462 0 0 0 7-10 yrs in SNS Atlanta, US 
80 At risk 105    1 ID patients Italy 
81 At risk 180 179   1 ID (unknown etiology) Italy 
30 
At risk 992 boys 981 10 1 0 
boys in school with learning 
difficulties 
 
Control 725 723 2 0 0 
non transmitting X chr from 
mother 
 
111 
At risk 37 chr 37 chr 0 0 0 Fragile X Finland 
Control 56 chr 56 chr 0 0 0 normal controls  
101 
At risk 206 chr 206 chr 0 0 0 FMR1 mutations  
Control 459 chr 459 chr 0 0 0 
healthy controls from 3 
populations 
Euro/American, 
Chinese, Finish 
104 At risk 1014 1014 0 0 0 
children 5-18 yrs with 
academic difficulties 
Baltimore City 
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Ref Population 
# of 
Individuals 
N
o
rm
a
l 
In
te
rm
ed
ia
te
 
P
re
m
u
ta
ti
o
n
 
F
u
ll
 M
u
ta
ti
o
n
 
Cohort Criteria Origin 
82 At risk 222   0 1 4-20yrs in SNS for ID Spanish 
130 At risk 17 17 0 0 0 
children identified with 
fragile site and negative for 
FMR1 expansions 
United Kingdom 
103 Control 610 chr    0 
unrelated normal X from 5 
populations  
Africa, Chinese, 
Greek/Cyrus, 
English, Indian 
110 At risk 534 525 8 1 0 
children 1.5-6 yrs referred 
for language delay 
 
39 
At risk 147 291  
chr 
2 
chr 
0 0
×
 females with POF London 
Control 1268 1263 5 0 0 
non transmitting X of boys 
with learning difficulties 
 
128 At risk 257 257    males 3-25 yrs with ID Greece/Cyrus 
127 
At risk 150 150 0 0 0 
Children 1.6-20 yrs with 
developmental delay + their 
mothers + four families with 
positive fragile site 
Chinese 
Control 77 136 chr 0 2 0 healthy adults  
46 At risk 2652 2629 22 1 0 children 7-10 yrs in SNS Atlanta, US 
47 
At risk 209 394 chr 0 0 0^ females with POF 
London/United 
Kingdom 
Control 2434 
4795 
chr 
0 0 0
~
 
mom's of boys with learning 
diff. 
 
126 At risk 611 611 0 0 0 
2-25 yrs with ID (excluded 
other syndromes) 
Cyrus/Greece 
125 At risk 62    0 children 1-17 yrs with ID Mexico 
124 At risk 144 144 0 0 0 
negative for FMR1 
expansions 
Brazil 
83 At risk 232    1 ID patients Italian 
123 At risk 206 206 0 0 0 
patients with ID in SNS or 
private care facility 
Taiwan 
34 At risk 3738 3687 41 2 1 boys 5-18 yrs in SNS England 
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Ref Population 
# of 
Individuals 
N
o
rm
a
l 
In
te
rm
ed
ia
te
 
P
re
m
u
ta
ti
o
n
 
F
u
ll
 M
u
ta
ti
o
n
 
Cohort Criteria Origin 
Control 2968 2917 19 0 0 mothers (other X chr)  
106 At risk 254 246 4 0 0 
Boys with developmental 
delay 
 
107 
At risk 130 157 chr    
individuals in SNS or home 
for ID 
New Delhi 
Control 135 225 chr      
108 At risk 146 146   0 
males & females living in an 
institution for ID 
 
84 At risk 114    1 
9-16 yrs in SNS with mild-
mod ID 
Croatia 
31 
At risk 276 265 3 0 0 
boys 2-18 yrs with ID or 
learning difficulties 
Brazil 
Control 207 204 0 0 0 
intellectually/physically 
normal males 
 
137 At risk 84 84 0 0 0 
males and females 2.6-28.6 
yrs referred for preliminary 
diagnosis of autism 
 
85 At risk 26 25   1 males & females with OCD Utah, US 
29 
At risk 203 190 13 0 0 males with PD Italy 
Control 370 369 1 0 0 
healthy males enrolled for 
aging study 
 
32 
At risk 198 274 chr 6 0 0 Parkinson's disease Spain 
Control 220 311 chr 3 0 0   
 
PDD = pervasive developmental disorder; ID = intellectual disability; yrs = years; SNS = special needs 
school; chr = chromosome; POF = premature ovarian failure; OCD = obsessive compulsive disorder; PD = 
Parkinson’s disease. + Reference 79: Two related females were found to harbour an FMR2 expansion; only 
one positive FMR2 expansion was identified in the screened cohort, however, the article reports on three 
additional FRAXE positive cases; 
× 
One female had a small deletion. ^Three women with a small deletion; 
~ 
One women with
 
 small deletion in control cohort. Most authors used the term MR (mental retardation) when 
the paper was published and, as this is no longer acceptable terminology, MR has been changed in the above 
table to ID.  
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Table S.2 – Primer Sequences 
 
Primer Name F Primer (5’ to 3’) R Primer (5’ to 3’) 
FRAXE 603F, 
598R 
CCTGTGAGTGTGTAAGTGTGTGATGCTGCCG GCGAGGAAGCGGCGGCAGTGGCACTGGG 
DXS7847 TTAAACTCTTGGATATGTATGCAC TTTGTCCTCTCCTCCCTTG 
DXS7393 GTCTATTTCAAACAAACACTTACC AACCTGACCACAGCTATCC 
DXS7389 CAACCCATTTCTTTTCCCTTC AGAAACCAAAAGAGATAACCAAAC 
DXS7390 GATTTGAATGCTTCCATTGCC ATTTCTAAAAATGACATACCCGAC 
DXS7394 TTCCCACTAGGTGATTCTG CGCTTGGAAACTATGATGAAATG 
DXS7812 CCTGTTACCTTAGTTTCTTCTG AAGATGTGCCTTCCTTCTG 
DXS1318 CCTCTCTGTGTGTTTCCCC TCCCCAAGCAAAACCAACATATTC 
DXS6729 TAAGACACCTTTATGCCCCA AAGGATGAGAAAAACAATCTAAGC 
DXS8303 TCCACCTCTGCAAAAAACAATTTC CCTCTGGTGTTTGGGGTTC 
DXS1185 TAGGGTCTGGAAATTGCTGA CACTCCCTCACTCACTCTC 
DXS457 CCTGACAATCACATAAGCTA TCTGGTCACAAGAATTTCAG 
DXS1123 TGCCTAAATGTTCGCAAGCCCATTC ACAAACAGCTGCCTCCTAGAAACCC 
DXS998 CAGCAATTTTTCAAAGGC AGATCATTCATATAACCTCAAAAGA 
DXS548 AGAGCTTCACTATGCAATGGAATC GTACATTAGAGTCACCTGTGGTGC 
DXS1215 GGGCAAAACATTAAACCTCTC GCCCTCTAAGTCATTACGCT 
DXS533 AATGTGGCAAGGAAGCCAGCA CAGTTTTCATTTCTCTGTCTTCAA 
DXS1193 AATTCTGACTCTGGGGC TTATTTTAAGGTGAGTATGGTGTGT 
DXS990 AGCTATATGACCAGTACAAACATAC GACAGAAGGGACATCAACTC 
DXS986 CCTAAGTGCTCATCATCCCA AGCTCAATCCAAGTTGCTGA 
DXS1226 CTAAACCCATCTGNCCTC TTTCCAGCAACTACCTTTCAT 
DXS1214 TAGAACCCAAATGACAACCA AAGATAGCAGGCAACAATAAGA 
DXS8055 AGTGGGTCACTCTAGTCATCAT TCAGGTTTCTGTGTGGACAT 
DXS991 ACTTCAACCACAGAAGCCTC ATCATTTGAGCCAATTCTCC 
DYS570 GAACTGTCTACAATGGCTCACG TCAGCATAGTCAAGAAACCAGACA 
DYS643 AAGCCATGCCTGGTTAAACT TGTAACCAAACACCACCCATT 
DYS490 CCTGGCAGGAATTATCCAGA GCAGAGCTTGCACTGAGCT 
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Table S.3 – Results of FMR2 PCR testing for the 92 boys from the retrospective cohort 
 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
00MG1022 14 01MG1617 14 03MG2219 3 11781 14 
00MG1052 12 01MG1684 12 03MG411 21 11820 12 
00MG1115 15 01MG318 12 03MG438 ** 11823 22 
00MG265 6 01MG818 13 03MG682 13 11987 13 
00MG267 12 01MG948 19 03MG979 13 12108 12 
00MG428 12 02MG1008 12 04MG1051 12 12134 17 
00MG457 12 02MG1106 21 04MG1495 12 12213 15 
00MG505 18 02MG1142 12 04MG1563 12 12273 ++ 
00MG56 21 02MG1229 12 04MG1870 17 12346 12 
00MG732 21 02MG139 12 04MG1871 17 12375 23 
00MG740 13 02MG1616 12 04MG452 12 12382 12 
00MG814 12 02MG1639 21 04MG742 16 12395 23 
00MG832 13 02MG1698 12 05MG319 8 12679 16 
00MG885 16 02MG1708 13 10570 12 12714 16 
00MG949 15 02MG2248 15 10573 12 12881 15 
00MG964 15 02MG580 12 11140 13 221 16 
01MG100 15 02MG948 13 11158 16 225 15 
01MG1028 13 03MG1146 12 11187 12 263 23 
01MG1029 16 03MG1298 25 11305 26 284 15 
01MG1070 21 03MG138 17 11312 21 306 15 
01MG1192 13 03MG1814 12 11324 13 311 15 
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Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
01MG1290 12 03MG2095 11 11757 15 317 12 
01MG1497 12 03MG2097 12 11769 16 363 16 
          ** = no amplicon; ++ = 2 alleles obtained; further investigation required 
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Table S.4 – Results of FMR2 PCR testing for the 14 boys from the Janeway cohort 
 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
330 9 365 16 370 16 375 18 
346 29 367 15 371 15 376 19 
347 15 368 23 372 15   
364 ++ 369 12 374 20   
         ++ = 2 alleles obtained; further investigation required 
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Table S.5 – Results of FMR2 PCR testing for 277 Newfoundland controls 
 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
C1 9 C72 12 C141 13 C212 12 
C2 12 C73 12 C142 12 C213 17 
C3 10 C74 16 C143 12 C214 12 
C4 13 C75 25 C144 12 C215 12 
C5 25 C76 15 C145 12 C216 13 
C6 15 C77 21 C146 14 C217 14 
C7 15 C78 27 C148 24 C218 21 
C8 10 C79 17 C149 16 C219 15 
C9 15 C80 12 C150 15 C220 12 
C10 18 C81 12 C151 12 C221 11 
C11 13 C82 25 C152 15 C222 13 
C12 12 C83 15 C153 14 C223 15 
C13 24 C84 12 C154 23 C224 15 
C14 12 C85 25 C155 12 C225 13 
C15 11 C86 15 C156 15 C226 12 
C16 25 C87 15 C157 ++ C227 13 
C17 13 C88 12 C158 11 C228 15 
C18 15 C89 15 C159 ++ C229 12 
C19 13 C90 12 C160 12 C230 12 
C20 12 C91 13 C161 14 C231 12 
C21 12 C92 17 C162 21 C232 12 
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Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
C22 18 C93 13 C163 15 C233 12 
C23 12 C94 15 C164 12 C234 13 
C24 15 C95 12 C166 12 C235 12 
C25 12 C96 15 C167 16 C236 12 
C26 12 C97 12 C168 12 C237 12 
C27 16 C98 12 C169 15 C238 12 
C28 13 C99 12 C170 15 C239 14 
C29 12 C100 12 C171 16 C240 12 
C30 13 C101 12 C172 17 C241 ++ 
C31 13 C102 13 C173 12 C242 16 
C32 13 C103 12 C174 ++ C243 ++ 
C33 17 C104 8 C175 15 C244 12 
C34 15 C105 13 C176 15 C245 15 
C35 13 C106 16 C177 12 C246 12 
C36 13 C107 18 C178 15 C247 21 
C37 13 C108 15 C179 12 C248 16 
C38 12 C109 13 C180 13 C249 12 
C39 15 C110 13 C181 17 C250 8 
C40 14 C111 14 C182 12 C251 15 
C41 12 C112 12 C183 ++ C252 23 
C42 23 C113 22 C184 15 C253 15 
C43 15 C114 8 C185 12 C254 12 
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Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
C44 12 C115 15 C186 13 C255 12 
C45 13 C116 22 C187 15 C256 12 
C46 15 C117 15 C188 12 C257 15 
C47 12 C118 12 C189 15 C258 12 
C48 11 C119 12 C190 12 C259 17 
C49 12, 25 C120 17 C191 12 C260 15 
C50 ** C121 12 C192 12 C261 13 
C51 13 C122 12 C193 12 C262 17 
C52 15 C123 13 C194 12 C263 12 
C53 15 C124 14 C195 13 C264 16 
C54 17 C125 21 C196 12 C265 12 
C55 13 C126 15 C197 ++ C266 12 
C56 8 C127 12 C198 13 C267 13 
C57 12 C128 11 C199 16 C268 ++ 
C58 24 C129 13 C200 18 C269 12 
C59 15 C130 15 C201 15 C270 15 
C60 12 C131 15 C202 13 C271 13 
C61 13 C132 13 C203 13 C272 14 
C62 12 C133 12 C204 14 C273 13 
C63 12 C134 13 C205 12 C274 19 
C64 20 C135 15 C206 13 C275 12 
C65 12 C136 12 C207 8 C276 12 
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Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
Sample ID 
FMR2 
Allele 
C67 13 C137 25 C208 15 C277 12 
C68 12 C138 12 C209 ++ C278 12 
C69 15 C139 12 C210 15 C279 12 
C70 15 C140 12 C211 12 C280 11 
C71 21       
         ** = no amplicon; ++ = 2 alleles obtained, further investigation required
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Appendix M – Expanded pedigrees 
 
 
 
 
Figure A.1 - Expanded pedigree for Family A 
Figure A.2 – Expanded pedigree for Family C 
Figure A.3 – Expanded pedigree for Family D 
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Figure A.1 – Expanded pedigree for Family A 
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Figure A.2 – Expanded pedigree for Family C 
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Figure A.3 – Expanded pedigree for Family D 
 
 
